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ABSTRACT
Predicting the clinical course of an early-stage oral tongue squamous cell carcinoma (OTSCC) 
is challenging, as even small tumors can behave aggressively. OTSCC oft en metastasizes to the 
cervical lymph nodes, and the presence of lymph node metastasis at the time of diagnosis is 
considered the most important tumor-related prognostic factor in OTSCC. Th e mechanisms 
of this disease progression are poorly understood. Despite slight improvement in the prognosis 
of OTSCC in recent decades, the outcome of these patients is still modest. Th erefore, a deeper 
understanding of the phenomena behind tumor progression would enable medical professionals 
to evaluate the aggressiveness of the disease and to adjust its treatment more eff ectively.
Th e extracellular matrix and basement membrane must be broken down before a tumor 
can invade surrounding tissues and further spread into blood and lymph vessels. Th is is a 
process that involves various proteolytic enzymes, the most important of which are matrix 
metalloproteinases (MMPs). Over 25 structurally related, but genetically distinct, human MMPs 
have been identifi ed and characterized: collagenases, gelatinases, stromelysins, matrilysins, 
membrane-type MMPs, and other MMPs. Certain MMPs, especially MMP-8, can also play an 
anti-metastatic and protective role in tumor development. 
Toll-like receptors (TLRs) are pattern-recognition molecules involved in innate immunity 
that are also expressed in many types of cancer. TLRs apparently play a pivotal role in malignant 
disease: they are related to tumor progression and, conversely, to cancer inhibition. Th eir 
expression pattern and role in oral cancer, however, remains unclear. 
In this thesis we studied the expression of MMPs 2, 7, 8, 9, 13, and 25 and TLRs 2, 4, 5, 7, 
and 9 in early-stage OTSCC, as well as their role in the disease progression and patient outcomes. 
Th e study comprised 73 consecutive clinically T1N0M0 and T2N0M0 OTSCC patients 
treated at the Helsinki University Hospital, Helsinki, Finland in 1992-2002. We prepared tissue 
array blocks from primary tumors and immunostained them. We also used whole section 
slides from patients with metastasized or recurrent disease. We compared immunoexpression 
of MMPs and TLRs to tumor and patient characteristics as well as to patient outcomes. We 
also used Western immunoblot to examine TLR-2 and -4 expression in the highly invasive and 
aggressive HSC-3 OTSCC cell line. In addition, we studied the eff ect of TLR-2 and -4 antagonist 
GIT27 (4,5-dihydro-5-isoxasoleacetic acid) on the invasion of the HSC-3 cell line in myoma 
organotypic invasion assay. 
OTSCC tumors expressed both MMPs and TLRs. Nuclear expression of MMP-13, but not 
cytoplasmic expression of MMP-2, -8, and -9, associated with deeper invasion and advanced 
tumor size. Furthermore, high nuclear MMP-13 expression predicted poor disease-specifi c 
survival. High MMP-7 protein expression associated with the presence of occult cervical 
metastases, increased invasion depth, and higher tumor grade, and also predicted poor outcome. 
Immunostaining of MMP-25 failed to correlate with any clinical parameters.  
High TLR-2, -4, and -9 expression correlated with deeper tumor invasion. Cytoplasmic 
expression of TLR-2 and -4 also correlated signifi cantly with higher tumor grade, whereas high 
TLR-5 expression associated with lower tumor grade. High expression of TLR-9 correlated 
with advanced tumor size. Negative or mild TLR-5 expression predicted poor disease-specifi c 
survival. 
OTSCC primary tumors, neck metastases and recurrent tumors expressed TLR-2, -4, and 
-9. TLR-2 and -4 antagonist GIT27 did not aff ect the invasion of the HSC-3 cell line in myoma 
organotypic invasion assay. Th us, TLRs may operate under a diff erent mechanism of action 
depending on whether they are activated by damage-associated molecular patterns in cancer or 
by pathogen-associated molecular patterns in infection. 
Our results suggest that MMP-7 and MMP-13 in particular may have prognostic value in 
OTSCC. Th eir use as prognostic biomarkers, however, calls for further study. TLR-2, -4, and 
-9 seemed to predict invasive tumor growth. Primary tumors and neck metastases as well as 
recurrent tumors of OTSCC express these TLRs, suggesting that TLRs seem to play a role in both 
the development and progression of tongue carcinoma. 
TIIVISTELMÄ
Kielisyövän käyttäytymisen ennustaminen on haastavaa, sillä jo pienet kielisyövät saattavat 
lähettää etäpesäkkeitä taudin varhaisessa vaiheessa. Etäpesäkkeiden esiintymistä kaulan 
imusolmukkeissa pidetään merkittävimpänä kasvaimeen liittyvänä tekijänä taudin 
ennustetta arvioitaessa. Huolimatta kielisyövän ennusteen hienoisesta paranemisesta viime 
vuosikymmenien aikana, taudin elossaoloennuste on edelleen varsin huono ja taudin 
etenemiseen vaikuttavat mekanismit tunnetaan huonosti. Näistä syistä johtuen olisi toivottavaa 
tuntea tarkemmin syövän taustalla piileviä biologisia mekanismeja, jotta taudin aggressiivisuutta 
voitaisiin arvioida paremmin ja mahdollisesti löytää myös kohdennettuja hoitomuotoja.
Jotta kasvainsolut voivat edetä ympäröivään kudokseen sekä veri- ja imusuoniin, 
proteolyyttisten entsyymien pitää hajottaa soluväliainetta ja tyvikalvo. Matriksin 
metalloproteinaaseilla (engl. matrix metalloproteinases, MMP) on tässä keskeinen osuus. 
Nykyisin tunnetaan yli 25 rakenteellisesti toisiaan muistuttavaa, mutta geneettisesti erilaista, 
MMP:a, jotka jaetaan eri ryhmiin: kollagenaasit, gelatinaasit, stromelysiinit, matrilysiinit, 
solukalvoihin liittyvät ja muut MMP:t. Aikaisempien tutkimusten valossa, eräät MMP:t, etenkin 
MMP-8, omaavat toisaalta myös syövältä suojaavia vaikutuksia. 
Tollin kaltaiset reseptorit (engl. toll-like receptors, TLR) ovat proteiineja, jotka tunnistavat 
elimistölle vieraita ja myös elimistön omia rakenteita, ja jotka säätelevät luonnollista 
immuniteettia. Tiettyjen TLR:ien on todettu ilmentyvän myös eräissä syövissä. TLR:eilla on 
havaittu sekä syöpää edistäviä että hidastavia vaikutuksia, mutta niiden merkitys, ja osin myös 
ilmentyminen, suusyövässä on vielä epäselvä. 
Tässä väitöskirjatyössä tutkittiin MMP:ien 2, 7, 8, 9, 13 ja 25:n sekä TLR:ien 2, 4, 5, 7 ja 
9 ilmentymistä varhaisvaiheen kielisyövissä sekä niiden merkitystä kasvaimen etenemisessä ja 
taudin ennusteessa.  
Tutkimusmateriaalimme koostui 73 potilaasta, joilla oli todettu kliinisesti T1N0M0 tai 
T2N0M0 kielisyöpä. Potilaat oli hoidettu Helsingin yliopistollisessa keskussairaalassa vuosina 
1992-2002. Emokasvaimista tehtiin tissue array -blokit, jotka värjättiin immunohistokemiallisin 
menetelmin. Kasvaimet, jotka olivat uusiutuneet tai lähettäneet etäpesäkkeitä, tutkittiin myös 
kokoleikkeitä käyttäen. Tutkittujen MMP:ien ja TLR:ien ilmentymistä syöpäkudoksessa verrattiin 
kasvaimen muihin ominaisuuksiin, potilaaseen liittyviin tekijöihin sekä taudin ennusteeseen. 
TLR-2:n ja -4:n ilmentymistä tutkittiin myös erittäin invasiivisessa ja aggressiivisessa HSC-3 
kielisyöpäsolulinjassa. Lisäksi tutkimme TLR-2:n ja -4:n vastavaikuttaja GIT27:n (4,5-dihydro-5-
isoxasoleacetic acid) vaikutusta kielisyöpäsolujen invaasioon myoomamallissa. 
MMP:t ja TLR:t ilmentyivät suuressa osassa kielisyöpäkasvaimia. MMP-13:n lisääntynyt 
ilmentyminen tumissa liittyi kasvaimen syvempään invaasioon ja suurempaan  kokoon sekä 
ennusti potilaiden lyhyempää elossaoloaikaa. Sen sijaan samanlaista vaikutusta ei todettu MMP-
2:n, -8:n ja -9:n ilmentymisellä syöpäsolujen solulimassa. MMP-7 ilmentyi voimakkaammin 
niillä potilailla, joilla todettiin kaulan etäpesäkkeet, kasvaimen syvempi invaasio tai huonompi 
erilaistumisaste. Lisääntynyt MMP-7-ekspressio ennusti myös potilaiden lyhyempää 
elossaoloaikaa. MMP-25:n ilmentyminen ei liittynyt mihinkään tutkittuun kliiniseen tekijään.  
Voimakas TLR-2, -4 ja -9 ilmentyminen liittyi kasvaimen syvempään invaasioon. Soluliman 
vahva TLR-2 ja -4 ilmentyminen liittyi lisäksi kasvaimen huonompaan erilaistumisasteeseen, 
kun taas TLR-5–proteiinia esiintyi enemmän korkeasti erilaistuneissa kasvaimissa. TLR-
9:n ilmentyminen oli voimakkaampaa kookkaissa kasvaimissa. Puuttuva tai vähäinen TLR-
5:n ilmentyminen puolestaan ennusti lyhyempää tautikohtaista elossaoloaikaa. TLR-2, -4 ja 
-9 ilmentyivät sekä kielisyövän emokasvaimissa että kaulan etäpesäkkeissä ja uusiutuneissa 
kasvaimissa. TLR-2:n ja -4:n vastavaikuttaja GIT27 ei vaikuttanut kielisyöpäsolujen invaasioon 
myoomamallissa. TLR:iden vaikutusmekanismi on mahdollisesti erilainen riippuen siitä, 
aktivoituvatko ne syövästä vai tulehduksesta johtuen. 
Tutkimuksemme perusteella etenkin MMP-7:lla ja -13:lla näyttäisi olevan ennusteellista 
merkitystä kielisyövässä. TLR-2, -4 ja -9 proteiinien ilmentyminen säätelee mahdollisesti 
kielisyövän invaasiota. Nämä TLR:t ilmentyivät sekä emokasvaimissa, kaulan etäpesäkkeissä 
että uusiutuneissa kasvaimissa, joten on todennäköistä, että TLR:eilla on jonkinlainen rooli niin 
kielisyövän synnyssä kuin sen etenemisessäkin. 
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INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, 
and half of these malignancies occur in the oral cavity (1). In Finland, approximately 3% of newly 
diagnosed cancers appear in the head and neck region (2). 
Oral tongue squamous cell carcinoma (OTSCC) is the most common cancer in the 
oral cavity. In Finland, 128 new cases of OTSCC were diagnosed in 2012, with male gender 
dominating slightly (2). Th e incidence of OTSCC shows signifi cant geographic variation 
worldwide; incidence is stable or falling in some regions, whereas in other areas, such as in 
Finland, incidence has risen slighly in recent decades (3-6).
Th e well-known risk factors for OTSCC include tobacco use and alcohol consumption, and 
their carcinogenic eff ects are multiplicative when combined (7-9). In addition, research suggests 
that poor oral hygiene and dietary factors contribute to oral carcinogenesis (10). A portion of 
oral premalignant lesions; leukoplakia, erythroplakia, and lichen planus, also progress to invasive 
carcinomas (7). Research has also shown an association between human papilloma virus (HPV) 
and oral squamous cell carcinoma (OSCC) (11). However, the precise role of HPV in OTSCC 
and the value of its surrogate marker, p16, remain inconclusive. 
Patients with OTSCC oft en present with tongue ulcers, throat pain, or a painless neck lump. 
Diagnosis is based on the clinical examination and histological assessment of a tumor biopsy. 
OTSCC spreads primarily through the lymphatic vessels and thus typically reaches the lymph 
nodes on the neck fi rst. Evaluating the primary tumor and regional metastasis generally requires 
computed tomography (CT) or magnetic resonance imaging (MRI) or both. CT of the chest 
also serves to rule out second primary tumors, which are relatively common, as well as distant 
metastases in cases of advanced diseases (12-15). 
Th e primary treatment of OTSCC is generally based on surgery, including resection of the 
primary tumor and neck dissection when indicated (16,17). Patients who present with advanced 
tumor size, a deeply invasive primary tumor or positive lymph nodes receive postoperative 
radiation or chemoirradiation treatment (18).
OTSCC is a disease with a modest survival rate; approximately one third of patients die 
from the disease, and the fi ve-year disease-specifi c survival (DSS) for advanced-stage (III-
IV) patients is only 30 to 50% (19-24). OTSCC reportedly has a higher rate of metastases and 
exhibits more aggressive behavior than do other carcinomas of the oral cavity, and even small 
tumors may metastasize in the early course of the disease (23,25-27). Th e presence of lymph 
node metastasis is considered the most important tumor-related prognostic factor in OTSCC 
(28-31). In addition to the clinical stage of the disease, which includes primary tumor size and 
invasion, neck node involvement and the possible presence of distant metastasis, the invasion 
pattern, perineural invasion, the carcinoma’s proximity to resection margins, the presence of 
extracapsular spread (ECS), and histopathological grade all have prognostic signifi gance in 
OTSCC (20,25,27,29,30,32-42). 
Th e extracellular matrix (ECM) and the basement membrane (BM) must be broken 
down before the tumor can spread into the blood and lymph vessels and, thus, metastasize, 
which crucially involves, among other proteolytic enzymes, matrix metalloproteinases 
(MMPs). Additionally, MMPs process several non-matrix bioactive substrates, such as 
cytokines, chemokines, immune mediators, other proteases, and cell adhesion proteins, which, 
consequently, direct immune responses (43). Over 25 human MMPs have been identifi ed, 
characterized, and divided into six groups according to their structure and substrate specifi city: 
collagenases, gelatinases, stromelysins, matrilysins, membrane-type MMPs, and other MMPs 
(44-47). MMPs are connected to invasion and metastasis in cancer (48), but are also shown to 
play an anti-metastatic and protective role in tumor development (48-52). Studies have found 
that overexpression of MMP-1, -2, -3, -7, -9, -13 and -14 in HNSCC contributes to invasion and 
metastasis and predicts poor survival (53-59). In contrast, MMP-8 overexpression in OTSCC has 
associated with higher survival rates (51). 
Toll-like receptors (TLRs), pattern-recognition proteins involved in innate and adaptive 
immunity, have both endogenous and exogenous ligands. Ten human TLRs have been identifi ed, 
each of which recognizes a specifi c microbial component (60). Many types of cancer also express 
TLRs, which are related to both tumor progression and cancer inhibition (61-64). Studies have 
shown that TLRs are expressed in the HNSCCs of diff erent subsites (65-77). However, their 
precise expression pattern and role in HNSCC remains unclear. 
A deeper understanding of the metastatic potential and the aggressiveness of the disease 
would be useful. Given the fairly poor survival outcome of these patients, as well as the 
considerable morbidity resulting from treatment, more individually tailored treatment based 
on more thorough knowledge of tumor behavior is necessary. Biomarkers could supply such 
information. Th is study aims to investigate the role of MMPs and TLRs in OTSCC. 

11.1 Oral tongue squamous cell 
carcinoma
1.1.1 Epidemiology and etiology
Th e oral cavity is a common site for squamous 
cell cancers of the upper aerodigestive tract, 
probably because it is the fi rst entry point 
for many carcinogens (78). Globally, 5% of 
cancers occur in the head and neck region, 
and approximately half of those occur in the 
oral cavity (1). Th e prevalence and incidence 
of oral cancer varies widely across countries 
(4,5). In Finland, head and neck cancer (HNC) 
comprises approximately 3% of all diagnosed 
cancers, oral cancer being the most common 
subtype (2). Th e Finnish Cancer Registry 
(www.cancerregistry.fi ) reports that 2012 saw 
128 newly diagnosed cases of OTSCC, with 
men representing 59% of cases (2). In recent 
decades, the incidence of OTSCC in Finland 
has been rising modestly (3,6). Patients 
diagnosed with OTSCC are oft en younger and 
healthier than patients diagnosed with oral 
cancer at other subsites (79).
Over 90% of oral cavity cancers are 
squamous cell carcinomas. Known risk 
factors include tobacco in diff erent forms and 
alcohol, which together account for about 
75% of HNCs; their eff ects are multiplicative 
when combined (5,7-9). Some evidence also 
reveals the infl uence of poor oral hygiene and 
dietary factors on the development of HNC 
(10). Most oral squamous cell carcinomas 
(OSCC) arise from premalignant lesions, 
such as leukoplakia, erythroplakia, and 
lichen planus. However, predicting which 
lesions will progress to invasive carcinoma is 
challenging (7). Studies have identifi ed HPV 
as a signifi cant contributor to oropharyngeal 
cancer (OPC) as well as its association with 
improved response to traditional treatment, 
whereas the incidence of HPV-related oral 
cancer is relatively low, and the infl uence of 
HPV on OSCC is currently unclear (80-82). 
However, a recent meta-analysis by Syrjänen 
et al. showed a strong association between oral 
potentially malignant disorders and HPV and 
OSCC (11).
Genetic predisposition also plays a role in 
the development of HNC; studies have linked a 
family history of HNC in a fi rst-degree relative 
as well as genetic polymorphisms in genes 
encoding enzymes involved in the metabolism 
of tobacco and alcohol to an elevated risk for 
developing the disease (5,83).
1.1.2 Diagnosis and classification
Th e diagnosis of OTSCC is based on clinical 
and histological examination of a tumor biopsy. 
Evaluating the size, extent and infi ltration of 
the primary tumor, as well as the presence of 
regional metastases, generally requires MRI 
or CT. Evaluation of the neck can also require 
ultrasound and ultrasound-guided fi ne-needle 
aspiration cytology. CT of the chest is widely 
used to evaluate distant metastasis and second 
primary tumors. Selective cases (e.g., when an 
uncertain radiological fi nding requires further 
evaluation) may require positron emission 
tomography-computed tomorgaphy (PET-
CT) (12-15).
However, not all imaging can successfully 
identify micrometastases. Th e detection of 
micrometastasis may require a sentinel lymph 
node biopsy (SNB) (84,85). Some centers favor 
SNB:  in a case of cT1 tumors with cN0 neck, 
for example, SNB, with a sensitivity of over 
90%, is recommended (84,86). 
Precise staging (Table 1) (87), based 
on clinical examination and radiological 
assessement, guides therapeutic decisions. 
Even though staging of the disease is the 
basis for treatment planning, this practice 
fails to take into account pathological or 
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2biological parameters other than tumor 
size, location, invasion and the presence of 
metastasis such as infi ltration depth, grade or 
immunohistological markers (8).   
Table 1. TNM and stage classifi cation for oral cavity squamous cell carcinoma.
T – Primary tumor  
Tx Primary tumor cannot be assessed
T0  No evidence of primary tumor
Tis  Carcinoma in situ
T1  ≤ 2 cm
T2  > 2 cm to 4 cm
T3  > 4 cm
T4a  Invades through cortical bone into deep/extrinsic muscles of the tongue, 
 maxillary sinus, skin
T4b  Invades masticator space, pteygoid plates, skull base, encases the internal carotid 
 artery
N – Regional lymph nodes 
NX  Regional lymph nodes cannot be assessed
N0  No regional lymph node metastasis
N1  Metastasis in a single ipsilateral lymph node ≤ 3 cm
N2  N2a Metastasis in a single ipsilateral lymph node > 3 cm to 6 cm
       N2b Metastasis in multiple ipsilateral lymph nodes ≤ 6 cm
       N2c Metastasis in bilateral or contralateral lymph nodes ≤ 6 cm
N3  Metastasis in a lymph node > 6 cm
M – Distant metastasis
M0  No distant metastasis
M1  Distant metastasis
Stage grouping
Stage 0 Tis N0  M0
Stage I T1 N0  M0
Stage II T2 N0  M0
Stage III T1, T2 N1  M0
 T3 N0, N1  M0
Stage IVA T1, T2, T3 N2  M0 
 T4a N0, N1, N2  M0
Stage IVB Any T N3  M0
 T4b Any N  M0
Stage IVC Any T Any N  M1
Modifi ed from TNM classifi cation of malignant tumours, 7th edition, Sobin L.H., Gospodarowicz M.K., 
Wittekind Ch, editors. Wiley-Blackwell, New York, 2009 (87). 
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31.1.3 Treatment
Treatment of the primary tumor 
Treatment planning is based on general 
guidelines, which can vary across centers 
and countries. Surgery alone is considered 
adequate in cases of early-stage disease (i.e., 
small local tumors) (36). Larger tumors, 
tumors with deep infi ltration, and those 
with metastases are generally treated with a 
combination of surgery and postoperative 
radiation or chemoirradiation (21,88). Surgical 
treatment includes resection of the primary 
tumor and neck dissection when indicated. 
Larger tumors oft en require reconstruction 
(88). OSCCs may be less sensitive to radiation 
and chemotherapy than are oropharyngeal or 
laryngeal cancers (78). 
Treatment of the neck
Th e lymph nodes of the neck are generally 
treated electively even though they are 
clinically normal, but if the risk for occult 
metastasis exceeds 15 to 20%. When the 
risk is lower, one can adopt a wait-and-see 
policy or perform a sentinel lymph node 
biopsy (7,30,89-91). Such elective treatment 
is generally surgical: elective neck dissection 
(END), oft en to neck levels ranging from I 
to IV (16,17). In practice, large T1 or more 
advanced tumors or tumors with deep 
invasion demand elective neck treatment. 
Abnormal lymph nodes detected during 
clinical examination usually undergo 
extended therapeutic neck dissection. Patients 
with histopathologically confi rmed neck 
metastasis receive postoperative radiation or 
chemoirradiation treatment. 
Oncological treatment
Advanced tumor size, deeply invasive primary 
tumor or positive lymph nodes call for 
postoperative radiotherapy to improve local 
disease control (8,78). In addition, positive 
surgical margins require further treatment, 
either re-operation or radiotherapy or both. 
Conventional radiation comprises 50 Gy for 
the neck and 56-70 Gy for the primary tumor 
area. Postoperative chemoradiotherapy, most 
oft en with cisplatin, is administered when 
multiple lymph nodes are involved or present 
extracapsular spread (ECS) or both (18). 
Chemotherapy may prolong survival by 8 to 
22% (92). 
1.1.4 Prognosis and prognostic 
factors
Even though the prognosis of OTSCC has 
improved slightly in recent decades, OTSCC 
remains a disease of modest survival, with 
approximately one third dying of the disease 
(19,21,22). In early-stage OTSCC, the fi ve-
year DSS is reportedly around 60 to 80%, 
whereas in advanced stages of the disease, the 
fi ve-year DSS drops to 30 to 50% (20-24). A 
multicenter international study comparing the 
outcomes of 2738 patients treated for OSCC 
between 1990 and 2000 to those between 2001 
and 2011 showed a signifi cant improvement 
from 59 to 70% in the OS of these patients 
(93). In Finland, the incidence of OTSCC 
has been rising in recent decades, yet reports 
indicate a slight improvement in survival: the 
fi ve-year age-standardized relative survival 
rose from 43 to 50% among men and from 
55 to 67% among women during 1964-2003 
(6). Approximately two-thirds of HNSCC 
patients present with advanced-stage disease 
commonly involving regional lymph nodes, 
and about 10% of patients present with distant 
metastasis at the time of diagnosis (8). Reports 
indicate that OTSCC has a higher metastasis 
rate and behaves more aggressively than other 
carcinomas of the oral cavity (25-27,39), 
but controversial results have shown no 
diff erences in survival between OTSCC and 
OSCCs of other subsites (94). Th e presence 
of occult neck metastases in early-stage 
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outcome (23,35). Furthermore, despite 
aggressive therapy, patients with stage I-II 
OTSCC oft en present with a lower rate of local 
tumor control and poorer survival than with 
many other types of cancer at an early stage 
(95,96).
Patient-related prognostic factors
Sociodemographic factors are considered 
to have only weak prognostic value in 
OSCC (34). Furthermore, age and gender 
as prognostic parameters in OTSCC remain 
controversial (26,97,98). Among patients 
with stage III–IV carcinomas, heavy alcohol 
consumption has signifi cantly associated 
with poor disease-specifi c survival (99). High 
alcohol consumption has also associated with 
higher rates of recurrent disease and second 
primary tumors (100). 
Clinocopathological prognostic factors 
TNM (tumor, node, metastasis) stage is the 
most important tumor-related prognostic 
factor in HNC, and the presence of neck 
metastases reduces the fi ve-year survival rate 
by 50%  (25,29,30,32,33,35,36,39). Other 
clinicopathological factors of prognostic 
signifi gance in OTSCC include the pattern of 
invasion, perineural invasion, the proximity 
of the carcinoma to resection margins, the 
presence of ECS, and histopathological grade 
(20,27,34,37,38,40-42).
In a study of 2258 OSCC patients with 
pathologically negative neck nodes, clinical 
nodal stage proved to be an independent 
prognostic predictor of outcome (101). Sayed 
et al. proposed that the lymph node ratio (the 
ratio of total positive nodes to total dissected 
nodes) would be a more accurate prognostic 
marker than the current N staging of TNM 
classifi cation in OSCC (102). A recent study of 
1617 OSCC patients showed that tumor size, 
nodal status, tumor subsite and bone invasion 
were the most infl uential predictors of disease 
recurrence and cancer-specifi c mortality 
probability (103).
Research has shown that the ECS of 
cervical lymph node metastasis decreases 
the fi ve-year survival rate by more than 50%, 
and ECS is considered a particularly reliable 
predictor for disease recurrence and death 
from HNSCC (25,29,104).
Th e best histological predictor of 
local metastasis and poor survival may 
be the infi ltration depth of the tumor 
(20,27,34,40,41). Tai et al. found that increased 
tumor thickness with perineural invasion 
predicts lower disease-specifi c survival and a 
higher lymph node metastasis rate in OTSCC 
and buccal SCC (38). In addition, multifocal 
perineural invasion alone has associated with 
with worse prognosis in OSCC (42). Moreover, 
infi ltration depth has proved to be one of the 
most important prognostic factors in OSCC, 
and some researchers have proposed including 
it in the TNM staging system (39). However, 
the value of tumor infi ltration for optimal 
treatment planning is limited due to poor 
specifi city in identifying high-risk patients, 
and the optimal cut-off  for tumor thickness 
to defi ne high-risk categories remains 
uncertain (35,39). Additionally, techniques for 
measuring the depth of infi ltration (or tumor 
thickness) have diff ered substantially between 
studies, so the results are diffi  cult to compare. 
Infi ltration depth can be measured either from 
the surface of the tumor to the deepest point 
of invasion or from the level of the adjacent 
mucosal lining. 
Several researcers have pointed out the 
signifi cance of resection margins in OSCC. 
Research has shown that compromised 
resection margins predict local recurrence 
and poor survival (20,105,106). However, 
what exactly constitutes a safe margin remains 
controversial (107-109).
In OSCC, evidence suggests that, 
regardless of the size of the primary tumor, 
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show a higher rate of local metastasis at 
presentation than do patients with well 
diff erentiated tumors (31,110). In a large 
population-based analysis of early-stage 
OSCC, high histologic grade associated 
with poor survival and carried independent 
prognostic value (111). However, the 
subjective nature of tumor grade evaluation 
and its poor specifi city limit its prognostic 
value (27,31,35,94). In a multivariate analysis 
of T1-2N0-1 tongue carcinoma patients, 
Shim et al. reported an association of higher 
tumor grade and deeper invasion with poor 
DSS, whereas advanced T classifi cation failed 
to predict prognosis (37). Bonnardot et al. 
made the same fi nding in early-stage (T1-T2) 
OTSCC; poor histological diff erentiation and 
tumor thickness increased risk of death (22). 
Tumor budding is a specifi c type of 
invasive growth in carcinomas characterized 
by single invading tumor cells or small clusters 
of tumor cells (< 5 cells) at the invasive front of 
the tumor. Th ese cells are more invasive than 
cells in the main tumor mass. A recent review 
of tumor budding in HNSCC suggested a 
strong association between tumor budding 
and tumor progression, as well as a strong 
correlation with prognosis (112). Furthermore, 
a retrospective multicentre study of tumor 
budding in early-stage OTSCC found a 
correlation between high tumor budding and 
DSS (113). Another study by the same group 
introduced a novel prognostic model for early-
stage OTSCC  which combined tumor budding 
and depth of infi ltration into a BD-model 
(114). Multivariate analysis showed that a 
high-risk BD-score correlated signifi cantly 
with loco-regional recurrence and DSS. Xie 
et al. also evaluated tumor budding in early-
stage OTSCC and found that tumor budding 
independently predicted the prognosis 
of these patients (115). However, before 
adapting tumor budding in daily practice 
to evaluate histological HNSCC specimens, 
standardization of scoring methods and the 
risk stratifi cation cut-off  point is essential. 
Tumorigenesis, tumor 
microenvironment and molecular 
markers in HNSCC
Hanahan and Weinberg have identifi ed eight 
hallmarks of cancer to describe the multistep 
and complex process of tumorigenesis (116). 
Th ese hallmarks include the ability of cancer 
cells to sustain proliferative signaling, evade 
growth suppressors, resist cell death, enable 
replicative immortality, induce angiogenesis, 
activate invasion and metastasis, reprogram 
energy metabolism and evade immune 
destruction. In addition, underlying these 
hallmarks are genome instability, a tumor 
microenvironment consisting of normal 
cells interacting with cancer cells, and 
infl ammation, all of which contribute to these 
hallmark functions. MMPs contribute to 
tumor angiogenesis and cancer cell invasion 
and metastasis, whereas TLRs are involved 
in infl ammation and cancer cells evading 
immune destruction.
Research has shown the tumor 
microenvironment to be a dynamic state 
containing a variety of components, including 
non-cancerous cells (i.e., immune cells, 
fi broblasts, angiogenic vascular cells) and 
an extra-cellular matrix milieu (consisting 
of fi bers, mainly collagen and fi bronectin, 
and soluble factors such as enzymes, growth 
factors, cytokines and chemocines) interacting 
with cancer cells (117,118). Th erefore, 
modifi cations in these components of the 
tumor microenvironment should infl uence the 
growth, invasion and spread of cancer cells. 
Currently, no therapy targeting the tumor 
microenvironment in OSCC is in clinical use 
(118). 
Epithelial-mesenchymal transition 
(EMT) plays a crucial role in cancer 
progression. Cancer cells undergoing EMT 
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enter to stroma, resulting in a favourable 
microenvironment for cancer progression 
and metastasis.  Han et al. investigated EMT 
through the measurement of E-cadherin 
(a transmembrane protein, which plays an 
important role in cell adhesion forming 
adherent junctions to bind cells within tissues 
together) and vimentin (a protein that is 
expressed in mesenchymal cells) in diff erent 
stages of OTSCC (119). Th ey found that 
EMT expression correlated with lymph node 
metastasis and DFS. 
Several molecular markers have been 
studied in HNSCC recently, with some of 
these markers also being adapted to clinical 
practice. MIB-1, for example, is widely used 
in evaluating salivary gland carcinomas 
(120,121). p16, a surrogate marker for HPV, 
is currently in clinical use in the diagnostics 
of OPC (122,123). Epidermal growth factor 
receptor (EGFR) has been widely examined 
in HNSCC (124), and cetuximab, an anti-
EGFR 1 monoclonal antibody, is commercially 
available and has been used to treat locally 
advanced HNC in combination with radiation 
therapy (18). Additionally, in OTSCC, 
several molecular markers have been studied, 
including oncoprotein cancerous inhibitor of 
PP2A (CIP2A) (125), Bmi-1, a protein that 
controls the cell cycle and the self-renewal 
of tissue stem cells (126), hypoxia-inducible 
factor-1α (HIF-1α) and cyclooxygenase-2 
(COX-2) (127), as well as numerous other 
proteins (27).
Th e role of biomarkers in decisions 
about the treatment of cN0 neck in HNSCC 
was evaluated in a review by Takes et al., 
who concluded that biomarkers may provide 
additional and complementary information 
and may even be able to identify patients at 
low risk for occult metastasis, but that due 
to the complexity of the metastatic process, 
identifying a single marker for metastasis is 
unlikely (128). Instead, techniques enabling 
the study of many factors simultaneously look 
promising.
Wikner et al. have reviewed circulating 
tumor cells in OSCC and suggest that OSCC is 
a systemic disease and that the investigation of 
circulating tumor cells from peripheral blood 
samples could off er new perpectives on the 
disease and provide an opportunity to identify 
potential targets for individualized therapies 
(129). Furthermore, the assessment of 
circulating tumor cells could aid in predicting 
disease recurrence. 
Cell-free DNA (cfDNA), meaning all the 
DNA outside the cells, is currently considered 
one of the most promising tumor markers 
(130-132). Circulating tumor DNA (ctDNA) 
is cell-free DNA released from tumor cells. 
ctDNA is present in a patient’s plasma and 
can serve, for example, in primary cancer 
diagnostics, the evaluation of treatment 
response and resistance, and the detection of 
residual disease. Next-generation sequencing 
(NGS), a technique that can identify rare 
mutant variants in complex mixtures of DNA, 
can serve in the further analysis of ctDNA 
(130).
1.2 Matrix metalloproteinases
1.2.1 Classification, expression, 
and regulation of MMPs
MMPs are enzymes that can degrade almost 
all ECM and BM proteins, which is essential 
for tumor cells to spread into the blood and 
lymph vessels and adjacent tissues (133). BM 
is a continuous sheet that supports cell layers, 
such as the epithelium and endothelium, and 
ECM is a collection of extracellular molecules 
secreted by cells that provides structural and 
biochemical support to the surrounding cells 
(133,134). ECM consists of structural proteins 
such as collagen and elastin; specialized 
proteins such as fi brillin, fi bronectin, and 
laminin; and proteoglycans. Most carcinomas 
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8overexpress these ECM proteins. In addition, 
MMPs process several non-matrix bioactive 
substrates, such as cytokines, chemokines, 
immune mediators, other proteases, and cell 
adhesion proteins, thereby modifying various 
cellular, immunologic, intracellular, apoptotic 
and anti-infl ammatory responses (135,136). 
Th us, MMPs play key roles in infl ammation 
and carcinogenesis, and generally in 
maintaining ECM homeostasis. 
Researchers have identifi ed and 
characterized over 25 diff erent MMPs with 
unique structures and diverse functions: 
collagenases, gelatinases, stromelysins, 
matrilysins, membrane-type MMPs 
(MT-MMPs), and other MMPs (Table 2) 
(44-47,133,137). 
In intact normal tissues, the activity and 
expression of most MMPs are maintained 
at undetectably low or quiescent levels (43). 
Since MMPs can degrade almost all tissue 
and structural components of connective 
tissue matrix and BMs, their activities require 
regulation at multiple levels: transcription, 
secretion, inhibition of activity, and changes 
in MMP localization either inside or outside 
the cell (47). Several pro-infl ammatory 
cytokines, hormones and growth factors can 
activate MMP gene transcription. Activation 
of inactive proenzymes (proMMPs) can occur 
in diff erent localizations: intracellularly, at the 
cell surface by MT-MMPs, or extracellularly by 
other proteases (138). MMPs can be activated 
by, for example, plasmin, trypsin, cysteine 
proteinases, and bacterial and candidal 
proteinases. Activated MMPs can further 
participate in the processing and activation 
of other MMPs in mutual activation cascades 
(43). Evidence suggests that the same MMP 
can have opposite eff ects based on the cell type 
in which expression occurs (49).
Th e function of diff erent MMPs depends 
on the local balance between them and their 
physiological inhibitors. Tissue-inhibitors 
of matrix metalloproteinases (TIMP) are 
endogenous inhibitors of MMPs consisting 
of four members (TIMPs 1-4). TIMPs share 
some structural features, but also exert 
specifi c and selective distinct biochemical 
characteristics and expression profi les (133). 
TIMPs 1-4 can inhibit all MMPs, but TIMP-1 
is a relatively ineff ective inhibitor of MMP-19 
and MT-MMPs (43). Th e primary function 
of TIMPs is considered MMP inhibition, 
but they also serve other functions such as 
MMP transportation and stabilization, MMP 
localization to the cell surface via MT-MMP 
binding, inhibition of angiogenesis, promotion 
of bone-resorbing activity, and growth factor-
like activity, as well as pro- and anti-apoptotic 
functions (134). 
Researchers have studied the expression 
and activity of diff erent MMPs in a variety of 
human cancers. MMP activation is linked to 
tumor progression both in early tumorigenesis 
(e.g., in malignant transformation, 
angiogenesis and tumor growth) and in 
late-stage tumor progression (48,133). Most 
prognostic studies have linked elevated levels 
of diff erent MMPs to tumor progression, 
invasion, metastasis and poor survival, 
but other researchers have also described 
an association with improved survival 
(49,51,139). Studies have shown that MMP-8, 
for example, has a protective infl uence against 
the spread of cancer in skin (52), breast (140), 
and tongue (51) cancers.
Studies have also reported upregulated 
production and enhanced MMP activation in 
breast, gastric, lung, vulva, and head and neck 
cancers, chondrosarcomas, and malignant 
melanomas (44,139), Furthermore, studies 
have shown that MMP overexpression in these 
cancers predicts tumor recurrence, metastasis, 
and invasion (44,139). Increased production 
of various MMPs (MMP-1, -2, -3, -7, -9, -13, 
and -14) reportedly associates with poor 
tumor diff erentiation, distant metastases, and 
shorter survival (48).
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on MMP inhibitors and cancer treatment 
also. Up-regulation of TIMPs in tumor 
cells may inhibit tumor invasion and 
metastasis, but TIMPs also serve functions 
not performed by synthetic MMP inhibitors 
(141). Although preclinical studies of the 
effi  cacy of MMP inhibitors in tumor models 
have been encouraging, the results of clinical 
trials in cancer patients have been somewhat 
disappointing, leading in some cases to tumor 
progression or severe side-eff ects (49,133). 
Furthermore, since most of the clinical trials 
have been conducted in patients with late-
stage disease, the question of whether MMP 
inhibitors benefi t early-stage cancer treatment 
remains unanswered (133).
1.2.2  Collagenases
Collagenases (MMP-1, -8, and -13) regulate 
cell growth and survival, and are thus strongly 
linked to cancer development and the invasion 
capacity of tumors as well as to various 
infl ammatory conditions (45). Collagenases 
diff er in their activation, substrate specifi cities, 
functional roles, and cellular localization (44). 
MMP-8 has a wide subtrate specifi city, 
and its activities overlap with those of other 
collagenases (142). MMP-8 may also play 
an anti-metastatic and protective role in 
tumor development as well as exhibit anti-
infl ammatory characteristics by processing 
anti-infl ammatory cytokines and chemokines 
and regulating infl ammatory cell apoptosis 
and immune response (48-52,142,143). 
MMP-13, a catalytically potent enzyme, 
seems to have a limited expression, but broad 
substrate specifi city (142). Overexpression 
of MMP-13 occurs in many conditions of 
pathological tissue destruction, such as 
infl ammation, infection and various types of 
cancer of invasive capacity (43).
1.2.3 Gelatinases
Gelatinases, MMP-2 and -9, have rather 
similar substrate specifi city cleave diff erent 
types of collagen and gelatin, and are, 
among other proteins, linked primarily to 
angiogenesis (44,133,135). However, the role 
of MMPs in angiogenesis seems uncertain, and 
evidence suggests that the eff ects of MMPs 
in angiogenesis may be context-dependent 
(133,135). Studies have shown that various 
cell lines such as keratinocytes, osteoclasts, 
eosinophils, neutrophils and macrophages 
express MMP-9, and that many infl ammatory 
cytokines can activate it (43). Th us, MMP-9 
overproduction and activation occurs in 
several infl ammatory and malignant diseases.
1.2.4  Matrilysins
MMP-7 (matrilysin-1) and MMP-26 
(matrilysin-2) constitute the matrilysin 
subfamily of MMPs and are expressed in 
normal and neoplastic epithelial tissue (144). 
Of these proteins, MMP-7 in particular is 
involved in broad proteolytic activity with 
the ability to degrade fi bronectin, laminin, 
nidogen, type IV collagen and proteoglycan 
core proteins as well as to activate other 
MMPs, thereby playing various roles in 
tissue remodeling (137,145). In physiological 
conditions, MMP-7 is expressed in normal 
ductal and glandular epithelium, but also 
associates with several malignant tumors, such 
as gastric, esophageal, colorectal, liver and 
pancreatic cancer (146-151).
MMP-7 expression is usually restricted to 
tumor cells, whereas other MMPs are usually 
expressed in the stromal tissue surrounding 
the tumor also (146,152). During tumor 
progression and invasion, MMP-7 has been 
shown to increase the apoptosis of cells 
adjacent to tumor cells while at the same time 
inhibiting cancer cell apoptosis (147,152). 
Furthermore, reviews have found that MMP-7 
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reduces cancer cell adhesion and promotes 
cellular proliferation and invasion (152). 
1.2.5 Membrane-type 
metalloproteinases
Th e group of MT-MMPs consist of six 
members: MMP-14, -15, -16, -17, -24, and 
-25. MMP-25, also known as membrane-type 
6 metalloproteinase (MT6-MMP), was fi rst 
observed in  polymorphonuclear leukocytes 
and can degrade type I-IV collagens, gelatin, 
fi bronectin and fi brin (153). A review by Sohail 
et al. reported MMP-25 expression in breast 
and colon cancer, and that the expression was 
linked to enhanced tumor invasion (154). 
Furthermore, studies have suggested that 
MMP-25 also plays a role in infl ammation and 
cellular migration (154-156).
1.2.6 MMPs in oral squamous 
cell carcinoma
In OSCC, MMPs have been studied relatively 
widely, but the role of MMPs in this disease 
remains somewhat unclear. Although 
previous studies show negative or lower 
MMP expression in normal oral mucosa than 
in OSCC, we are aware of no studies that 
have examined MMP expression specifi cally 
in normal oral tongue tissue (53,157-161). 
Research has shown that MMPs are expressed 
in OSCCs at diff erent subsites, including the 
tongue (51,53-55,58,157,160,162-164). de 
Vicente et al. studied MMP-7 expression in 
OSCC and observed expression only in cancer 
cells (58). Chuang et al., in contrast, found 
MMP-7 immunostaining in both tumors and 
the non-neoplastic buccal epithelium, but 
active MMP-7 was present only in tumor nests 
(157). Kusukawa et al. has examined MMP-3 
expression and reported its expression in 
early-stage OSCC tissue, but not in the 
normal epithelium (53). Th ey also found a 
correlation between high MMP-3 expression 
and advanced tumor size. Another study of 
MMP-13 in OSCC also reported a correlation 
between increased expression and larger T 
stage (158). 
A study of MMP-1, -2, -3, and -9 
expression in a series of 96 patients with 
OSCC revealed that elevated expression of 
all these MMPs correlates with the mode of 
tumor invasion (the reference describes the 
grading of the mode of tumor invasion in 
detail) (54). In addition, MMP-1, -2, and -9 
expression associated with the loss of ECMs, 
suggesting that tumor progression depends 
on the ability of tumor cells to degrade ECM 
(54). MMPs could thus play an important 
role in the invasion of OSCC. Kusukawa et 
al. reported a similar fi nding in early-stage 
OSCC in which high MMP-3 expression 
correlated with deeper invasion (53). Another 
study consisting of SCC of the tongue and the 
lower lip found that overexpression of MMP-7 
associated with high-grade disease (163). 
In OSCC, MMP-1, -2, -3, and -9 
overexpression has shown a positive 
correlation with nodal status (53,54,160). 
Furthermore, Kurahara et al. observed 
TIMP-1 overexpression in metastatic cases 
of OSCC. Similarly, Hong et al. found a 
correlation between MMP-9 overexpression 
and metastasis in OSCC, whereas MMP-2 
expression showed no such correlation (160). 
Th e authors suggested that MMP-9 may play 
a more important role in the metastasis of 
OSCC than does MMP-2. Aparna et al. also 
reported a correlation between increased 
MMP-2 and -9 expression and regional and 
distant metastasis in early-stage OTSCC 
(164). Furthermore, another study found an 
association between MMP-13 overexpression 
and the presence of lymph node metastases in 
OSCC (158).
Th e same study by Aparna et al. found 
that overexpression of both MMP- 2 and -9 
correlated with local recurrence and shorter 
survival in OTSCC, which is in accordance 
with a study by Yoshizaki et al., who found 
Review of the literature
11
that MMP-2 overexpression correlated with 
local, nodal and distant metastatic tumor 
recurrence as well with shorter DFS (55). 
Likewise, MMP-9 expression appeared to 
predict tumor metastases and shorter DSS in 
early-stage (T1N0M0 and T2N0M0) OSCC 
(162). In addition, a recent study by Vincent-
Chong et al. reported an association between 
MMP-13 overexpression and poor survival in 
OSCC (158).
As pointed out previously, MMPs 
have also been linked to improved survival 
among cancer patients. Korpi et al. made an 
interesting observation of MMP-8 expression 
and prognosis in OTSCC of diff erent stages 
(51). Overexpression of MMP-8 associated 
with improved survival, and the tendency 
was particularly prominent among women, 
suggesting that the possible protective role 
of MMP-8 in OTSCC progression could be 
related to estrogen. 
1.2.7 MMPs in head and neck 
cancer of other subsites
Researchers have shown that HNCs, as well as 
cancers outside the oral cavity, express diff erent 
MMPs, but because studies include cancers of 
diff erent subsites and stages, their results are 
diffi  cult to compare (53-56,75,165-171). 
A study by O-Charoenrat et al. found 
a correlation between MMP-9 expression 
and advanced T-stage in HNSCC of 
diff erent subsites (oral cavity, oropharynx, 
hypopharynx, larynx) (165). Other studies 
have shown that overexpression of MMPs 
to plays a role in the invasion of HNSCC at 
diff erent subsites (53-56,58,158). MMP-9 
(165) and MMP-13 (56) expression reportedly 
correlate with infi ltrative patterns of growth 
in HNSCC. In addition, other studies have 
found that MMP-13 plays a relevant role in 
the progression and invasion of other invasive 
malignancies (172,173). In LSCC, a study by 
Cazorla et al. found that a well-diff erentiated 
histology correlated with high MMP-13 
expression (174).
Studies have shown that overexpression 
of MMPs plays a role in the invasion and 
metastasis of HNSCC (53-56). In a study by 
O-Charoenrat et al. of carcinomas at diff erent 
H&N subsites (oral cavity, oropharynx, 
hypopharynx, larynx), MMP-9 overexpression 
correlated strongly with lymph node 
involvement, whereas MMP-2 expression 
correlated only weakly with lymph node status 
(165). Furthermore, one study of MMP-13 in 
HNSCC patients showed that upregulation 
of MMP-13 serum levels correlated with 
lymph node metastasis (175). In Stage I-IV 
LSCC, TIMP-3 expression correlated with 
the presence of lymph node metastases and 
MMP-2 expression (171). 
In HNSCC, MMP-7 overexpression 
has been linked to shorter survival and the 
presence of nodal metastases (58,59). In 
salivary gland carcinoma, low MMP-7 and 
high MMP-13 expression correlated with poor 
survival (176,177). Furthermore, MMP-13 
overexpression associated with poor survival 
in Stage I-IV HNSCC (57). Both MMP-2 and 
-9 expression have been reported to associate 
with shorter DSS and DFS in HNSCC 
(169,170). Pradhan-Palikhe et al. reported that 
plasma levels of TIMP-2, but not of MMP-8, 
predicted poor survival in HNSCC (178).
1.3 TOLL-LIKE RECEPTORS
1.3.1 TLRs in immune defence 
and cancer
Toll like receptors (TLRs) are pattern-
recognition receptors expressed by cells of the 
immune system and epithelial cells located 
near the host-environment boundary. TLRs 
are also present in many types of cancer, 
and multiple factors aff ect the variable and 
complex function of each TLR (60).
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In humans, ten diff erent TLRs have been 
identifi ed, each recognizing a specifi c microbial 
component (179). All TLRs, except TLR-3, 
activate the MyD88 (myeloid diff erentiation 
primary response gene 88) signaling pathway, 
which subsequently activates downstream 
transcription factors, such as nuclear factor 
kappaB (NF-κB), and mitogen-associated 
protein (MAP) kinase signaling pathways, 
leading ultimately to the expression of a 
wide variety of proinfl ammatory cytokines, 
chemokines, growth factors, collagenases, and 
antiapoptotic proteins (60,61,179). 
Researchers have identifi ed two kinds 
of ligands for TLRs: exogenous pathogen-
associated molecular patterns (PAMPs), which 
are components of microbes, and endogenous 
damage-associated molecular patterns 
(DAMPs) released from injured or infl amed 
tissues (60). Th us, the absence of foreign 
pathogens could elicite a TLR-mediated 
immune response.
TLR-2 and TLR-4 recognize 
lipopolysaccharide (LPS, a membrane 
component of Gram-negative bacteria), 
TLR-5 recognizes bacterial fl agellin, TLR-7 
recognizes double- or single-stranded RNA, 
and TLR-9 recognizes bacterial DNA (63,180). 
Th e location of each TLR in the cell is based 
on its function: TLRs detecting bacterial 
LPS and lipoproteins are normally located 
on the cell surface (TLR-1, TLR-2, TLR-4, 
TLR-5, and TLR-6), whereas TLR-3, -7, -8, 
and -9, which mainly recognize viral RNA 
and bacterial DNA, are located in endosomes 
and lysosomes, where these materials are 
processed (60). 
Studies have detected TLR 
expression in normal oral epithelium 
(67,69,70,72,75,181,182) as well as in 
premalignant oral lesions (181,183). 
Consequently, TLR activation regulates 
innate and adaptive immune responses (60). 
Th e actual role of TLRs in tumorigenesis 
remains controversial, as they are related 
to both cancer progression and inhibition 
(61-63). Tumor progression seems to 
result from TLR activation in tumor cells, 
whereas tumor regression associates with the 
activation of host immune responses (63). 
NF-κB activation occurs in most tumor cells, 
and TLRs are presumably among the major 
activators of this pathway (61). 
Th e relationship between infl ammation 
and tumorigenesis has recently become 
widely accepted; estimates indicate that 20% 
of all cancer-related deaths are associated 
with chronic infection and infl ammation 
(61). Studies indicate that tumor cells acquire 
many properties characteristic of immune 
cells, which allows them to communicate and 
regulate the immune system to promote their 
own survival and growth (61,116). Previous 
studies have demonstrated that TLR agonists 
may have potent immunostimulatory eff ects 
in vivo as a result of triggering de novo or 
boosting pre-existing (natural or therapy-
elicited) anti-cancer immune responses. Th e 
FDA has licensed three TLR agonists for use 
in cancer patients: bacillus Calmette-Guérin 
(BCG), which operates as a mixed TLR-2/-4 
agonist; monophosphoryl lipid A (MPL), a 
potent agonist of TLR-4; and imiquimod, a 
synthetic TLR-7 agonist (184). Imiquimod 
widely serves in the nonsurgical treatment 
for basal cell carcinoma (185,186). However, 
a precise elucidation of TLR-activated cell-
intrinsic and cell-extrinsic signaling pathways, 
and also identifi cation of biological markers 
that predict the propensity of an individual 
patient to benefi t from TLR agonists, are 
needed (184).
Researchers have studied the expression 
of diff erent TLRs in various cancers, 
including lung, prostate, breast, skin, and 
follicular thyroid carcinoma, as well as several 
gastrointestinal and gynecological cancers 
(187-193). Th ese studies have shown that TLR 
expression serves both pro- and anti-tumor 
functions. 
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1.3.2 TLRs in oral squamous cell 
carcinoma
Numerous studies have shown that the 
HNSCCs of diff erent subsites express TLR-2, 
-3, -4, -5, -7, and -9 both in vitro (66,71,74-
76,182,194-196) and in vivo (65-77).
Studies have also shown that TLRs 
contribute to the progression of OSCC. Ng 
et al. studied TLR-2 expression in OSCC and 
hyperplastic/dysplastic oral lesions (183). Cells 
(chronic infl ammatory cells, endothelial cells) 
of the OSCC microenvironment and dysplasia 
showed clearly higher TLR-2 expression than 
did cells of hyperplasia. TLR-2 expression 
occurred on the keratinocytes of dysplastic 
epithelium and OSCC, but not on the 
keratinocytes of hyperplastic samples. Positive 
TLR-2 expression in the microenvironment 
suggests that immune surveillance is activated 
against altered cells, whereas TLR-2 expression 
by malignant keratonicytes may correlate with 
apoptosis resistance and the survival of tumor 
cells. 
A recent investigation found higher 
TLR-3 expression in both OSCC cells and 
tissue samples than in normal oral epithelial 
tissue (72). Luo et al. found that TLR-3 
activation induces apoptosis of OSCC cells 
and that the administration of TLR-3 agonist 
inhibits OSCC tumor growth in vivo in a 
murine model (72). Th ey concluded that 
TLR-3 has anticancer eff ects in OSCC. He et al. 
also investigated the expression and function 
of TLR-3 in OSCC (66). TLR-3 was expressed 
in both the OSCC tissue and the two OSCC 
cell lines examined. Activation of TLR-3 with 
lyophilized polyinosinic-polycytidylic acid 
(Poly(I:C)) upregulated cytokine expression, 
reduced cell viability by suppressing cell 
proliferation and inducing apoptosis, and 
limited cell migration in OSCC. Th us, TLR-3 
activation might aff ect OSCC development. 
In contrast, Chuang et al. found that TLR-3 
expression contributes to tumor invasion in 
HNSCC (71). Cytoplasmic TLR-3 staining 
occurred in the vast majority (73%) of OSCC 
(Stage I-IV) tissues, and strong expression 
correlated with poor diff erentiation and 
perineural invasion. 
When studying Stage I-IV OSCC tissue 
samples, normal oral mucosa, and OSCC cell 
lines, Sun et al. detected weak TLR-4 expression 
on the normal mucosa adjacent to the tumor 
(182). In OSCC, TLR-4 correlated inversily 
with grade: expression was weak in poorly 
diff erentiated tumors. High TLR-4 expression 
occurred in OSCC cell lines, which showed 
resistance to cisplatin-mediated apoptosis 
aft er pretreatment with TLR-4 ligand LPS. 
Th e authors concluded that the development 
of resistance to cisplatin in human OSCC 
might occur through a mechanism involving 
TLR-4 and its signaling pathway. Suppression 
of TLR-4 and its signaling pathway could thus 
increase sensitivity to cisplatin. Szczepanski 
et al. studied TLR-4 in advanced-stage (III-
IV) OSCC and laryngeal squamous cell 
carcinomas (LSCC) (75). All tumors and 
HNSCC cell lines showed TLR-4 expression, 
which occurred in as many as 9/10 of normal 
oral mucosa, although cytoplasmic expression 
of TLR-4 in non-neoplastic tissue was weaker 
than that in the malignant tissue. TLR-4 
expression intensity correlated inversily with 
tumor grade: poorly diff erentiated tumors 
express little TLR-4, as the previous study 
by Sun et al. showed (182). TLR-4 triggering 
protected tumor cells from lysis mediated by 
NK-92 cells, but LPS binding to TLR-4 on 
tumor cells enhanced cell proliferation. Based 
on these fi ndings, Szczepanski et al. concluded 
that TLR-4 expression contributes to HNSCC 
progression and protects the tumor from 
immune system attack (75). 
Researchers have also examined TLR-4 
and -5 in early-stage (T1-2N0M0) OSCC and 
cutaneous squamous cell carcinoma (CSCC) 
(67). TLR-4 expression was similar in OSCC 
and CSCC tumors, but TLR-5 expression 
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was more abundant in OSCC than in CSCC. 
TLR-5 ligand fl agellin had no eff ect on the 
HSC-3 cell line, but did induce the migration 
and invasion of less aggressive mucocutaneous 
cell lines. 
A study of TLR-5 expression in OTSCC 
found that strong expression was an 
independent predictor of cancer mortality 
and disease recurrence (70). TLR-5 expression 
occurred in 84 of 101 normal epithelial 
and in 118 of 119 OTSCC samples, and the 
expression was stronger in OTSCC than in 
normal epithelium. In OTSCC, higher TLR-5 
expression associated with age > 70 years, 
female gender and disease recurrence. TLR-5 
expression showed no association with grade, 
stage or treatment. 
Helicobacter pylori (HP) is a fl agellated, 
Gram-negative bacteria believed to be the most 
common source of chronic bacterial incfection 
in humans (68). Since the recognition of 
bacterial fl agella involves TLR-5, which is 
thought to promote tumor growth through 
infl ammation-dependent mechanisms in 
epithelial cells, Grimm et al. studied TLR-5 
expression together with HP expression in 
Stage I-IV OSCC and in two OSCC cell lines 
(68). Th ey detected HP in 21.5% of OSCCs 
and found that HP expression associated with 
reduced DFS. Multivariate analysis showed HP 
expression to be an independent prognostic 
factor in OSCC. TLR-5 expression was absent 
from normal oral mucosa, but overexpressed 
in OSCC. However, TLR-5 expression showed 
no correlation with either clinicopathological 
characteristics or survival. 
A study by Ahn et al. showed that TLR-7 
agonist imiquimod inhibited OSCC cell 
proliferation in a dose-dependent manner 
(195). Imiquimod also induced necrotic cell 
death in OSCC cells. Th e authors concluded 
that imiquimod eff ectively inhibited OSCC cell 
growth by inducing apoptosis and necrosis. 
Th us, imiquimod could be considered an 
eff ective therapeutic for OSCC. 
A study by Kauppila et al. found that 
high TLR-9 expression was an independent 
prognostic factor in Stage I-IV OTSCC (69). 
TLR-9 also mediated OTSCC invasion in 
vitro. TLR-9 expression occurred in 181 of 
195 OTSCC tissue samples and was higher 
in OTSCC than in normal epithelium. 
High TLR-9 expression associated with 
high MMP-13 expression and poor tumor 
diff erentation (grade). TLR-9 ligand 
CpG-ODN increased OTSCC cell invasion and 
migration. TLR-9 siRNA (small interfering 
RNA) and inhibition by TLR-9 antibodies, in 
contrast, reduced OTSCC cell invasion and 
migration. Park et al. examined whether OSCC 
tumor progression involve TLR signaling 
(196).  TLR-2, -3, -4, -5, -7, and -9 expression 
occurred in OSCC cells, but TLR-2 and TLR-5 
activation by bacterial LPS and fl agellin did 
not aff ect OSCC tumor cell progression. Th e 
more recent fi ndings of Kauppila et al. (69) 
confi rmed the previous fi ndings of Min et al., 
who also studied TLR-9 expression in Stage 
I-IV OSCC tissue samples and OSCC cell 
lines (73); both found that TLR-9 expression 
was higher in OSCC tissue than in adjacent 
normal tissue. High TLR-9 expression levels 
associated with tumor size, clinical stage, and 
a high Ki-67 positive rate in OSCC. TLR-9 
expression also occurred in the OSCC cell 
line, and stimulation with TLR-9 agonist 
CpG-ODN increased OSCC cell proliferation. 
Ruan et al. also published another study of 
TLR-9 expression in the OSCC cell line and 
found that TLR-9 activation induced OSCC 
cell migration and invasion (194).  Elevated 
MMP-2 expression, secretion and activity also 
occurred during treatment with TLR-9 agonist 
CpG-ODN. Th us, TLR-9 signaling activation 
could promote human oral cancer invasion 
with MMP-2 induction.
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1.3.3 TLRs in head and neck 
squamous cell carcinoma of 
other subsites
Rydberg et al. studied TLR-2, -3, and -5 
expression in LSCC, a pharyngeal squamous 
cell carcinoma cell line, a healthy bronchial 
epithelial cell line, and in primary human nasal 
epithelial cells (74). Th ey detected all these 
TLRs in the LSCC with the weakest TLR-3 
expression. Th e TLR staining intensity varied 
among the diff erent tumour cells within the 
HNSCC, which indicates that SCCs comprise 
a heterogenic cell population. Bronchial cells 
expressed mainly TLR-3, and nasal epithelial 
cells TLR-2, -3, and -5. TLR agonists induced 
a signifi cant response in HNSCC cell lines, 
characterized by infl ammation and cell 
death. Normal epithelial cells showed no such 
response. Th us, their results indicate that, the 
TLR system is an important target for future 
anti-tumor immunotherapy. Another study 
of advanced-stage (III-IV) LSCC, TLR-2, -3, 
and -4 expression occurred in both LSCC 
and infl ammatory cells in tumor masses and 
tumor stroma. Th is observation may partly 
explain how tumors escape immune system 
surveillance (77). 
Ilmarinen et al. evaluated the malignant 
transformation rate of laryngeal papillomas 
(LPs) and the potential of TLR-2, -4, and -9 
immunoexpression as indicators of increased 
cancer risk in these patients (65). LSCC 
occurred in 2.8% of patients with recurrent 
respiratory papillomatosis. Nuclear TLR-4 
staining was lower in LPs transforming 
into LSCC than in LPs with no malignant 
transformation. High cytoplasmic TLR-4 
expression was typical of moderately or poorly 
diff erentiated tumors as well as of more the 
advanced T stage and, thus, may be associated 
with more aggressive disease. Cytoplasmic 
TLR-9 expression was lower in LPs than in 
LSCC. 
Pries et al. studied all human TLRs (TLR-
1-10) in HNSCC tissue samples from diff erent 
anatomical sites (pharynx, tongue, larynx, 
oral cavity) as well as in tumor-draining 
lymph nodes, tonsillar tissue, healthy nasal 
mucosa, normal oropharyngeal mucosa and 
eight HNSCC cell lines (76). All HNSCC 
cell lines and 80% of solid tumors (primary 
tumors and lymph node metastases) expressed 
only TLR-3 as a predominantly intracellular 
protein while no other TLRs were expressed. 
TLR-3 expression occurred only in malignant 
cells and strongly associated with high protein 
levels and activity of transcriptional activator 
NF-?B. Inhibition of TLR-3 expression in 
HNSCC cell lines reduced oncoprotein c-Myc 
expression and reduced cell proliferation; 
correspondingly, TLR-3 overexpression 
in murine fi broblasts resulted in c-Myc 
upregulation and increased cell proliferation. 
Th eir data suggested that TLR-3 contributes to 
the malignant phenotype leading to invasive 
carcinoma in HNSCC. 
1.4 Human papilloma virus 
and p16
Th e surrogate marker for human papilloma 
virus (HPV), p16, is widely utilized in 
evaluating oropharyngeal carcinomas, but 
its role in oral carcinoma remains unclear 
(122,197-200). In OSCC, p16 is seldom 
positive (201-205). 
Even though p16 serves as a surrogate 
marker for HPV in OPC, it does not 
strictly correlate with HPV positivity (122). 
Interestingly, in a study of 167 patients with 
early-stage OTSCC, patients with tumors 
showing p16 overexpression were at higher risk 
of death and disease recurrence. In addition 
the concordance between p16 expression 
and HPV infection was poor (206). Th us, 
based on this study by Ramshankar et al., the 
prognostic signifi gance of p16 in OSCC diff ers 
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from that reported in OPC (200). In contrast, 
in another study of 25 young adults (aged 
18 to 39 years) with OTSCC, p16 positivity 
correlated with improved relapse-free survival 
and overall survival (207). In the same study, 
p16 overexpression failed to reliably correlate 
with HPV positivity. 
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2 AIMS OF THE STUDY
Th e main purpose of this study was to clarify the role of MMPs (2, 7, 8, 9, 13, and 25) and TLRs 
(2, 4, 5, 7, and 9) in clinically early-stage oral tongue squamous cell carcinoma (OTSCC). New 
information and understanding of the function as well as the prognostic and clinical signifi cance 
of these proteins in OTSCC could lead to more precise evaluation of the aggressiveness of the 
disease and enable doctors to adjust their patients’ treatment more accurately in the future. 
Identifying patients presenting with T1-T2, N0 disease with poor prognosis who would benefi t 
from more aggressive treatment would prove especially useful.
Th e specifi c aims of the present study were: 
1. To investigate the expression of MMP-2, -7, -8, -9, -13, and -25 in clinically early-stage 
OTSCCs and to determine whether the expression of these proteins is associated with 
clinicopathological parameters or patient outcomes.
2. To examine the expression of TLR-2, -4, -5, -7, and -9 in OTSCC tumor tissue samples 
and their association with clinicopathological variables and survival. 
3. To characterize the expression of TLR-2, -4, and -9 in primary, metastasized and 
recurrent OTSCCs, and to evaluate the eff ect of TLR-2 and -4 antagonist GIT27 on the 
invasion of OTSCC cells in myoma organotypic invasion assay.  
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3.1 Patients (I, II, III, IV)
Our study comprised 73 patients with 
consecutive clinically T1N0M0 or T2N0M0 
OTSCC patients. Keski-Säntti et al. has 
described the clinical management of these 
patients in detail (35). Patients were treated 
with curative intent at the Helsinki University 
Central Hospital, Helsinki, Finland, in 1992-
2002. Th e patients’ demographic data appear 
in Table 3. 
Clinical data and cause of death were 
retrieved from patient records and Statistics 
Finland, the national agency for population 
statistics. Tumor samples from 73 patients 
were available for immunohistochemistry (36 
males and 37 females, median age 59 years, 
range 23-95 years), 48% (35/73) of which were 
clinically classifi ed as T1, and 52% (38/73) as 
T2. An experienced head and neck pathologist 
re-evaluated all original histological tumor 
specimens. According to histopathological 
classifi cation, 52 tumors (71%) were classifi ed 
as pT1, and 21 (29%) as pT2. Tumor invasion 
depth was measured from the level of the 
proximate normal mucosal surface. 
All patients in this study received 
treatment according to the Finnish national 
guidelines for the treatment of head and neck 
cancer. Regarding treatment of the neck, 31 
patients underwent no further treatment 
primarily for the neck (follow-up only), 41 
patients underwent elective neck dissection, 
and one patient received radiation therapy 
without surgery. Only those patients with 
deeply invasive early OTSCC tumors or 
who had neck metastases in neck dissection 
specimens received post-operative radiation 
therapy. Th us, radiation therapy had no eff ect 
on the evaluation of tumor characteristics 
or on the evaluation of occult metastases, 
except possibly in one patient. Of all patients, 
34 underwent post-operative radiotherapy, 
including neck in 33 patients.
Altogether 24 (33%) patients had occult 
neck metastases (i.e., lymph node metastases) 
in elective neck dissection specimens (n 
= 15) or neck metastasis during follow-up 
without failure at the primary site (n = 9). 
During follow-up, ten patients developed 
local recurrences. Only two patients were 
diagnosed with distant metastases, both aft er 
a locoregional recurrence. Eleven patients had 
a second primary tumor. All but one patient 
had a minimum follow-up time of fi ve years or 
until death (median 7.6 years, range 0.3-17.2), 
during which time 19 patients died of tongue 
cancer and 22 of other causes.
Study IV
To examine TLR expression in metastatic and 
recurrent disease, for Study IV we selected 
patients with occult neck metastases in END 
at the time of diagnosis, or the appearance 
of metastatic disease during follow-up, or 
a recurrent primary tumor (n = 30). In nine 
cases, recurrent tumors were inoperable. 
Tumor samples from 21 patients were 
available for immunohistochemistry (21 
primary tumors, 10 occult neck metastases 
in END, 5 neck metastases during follow-up 
(without previous treatment of the neck or 
failure at the primary site), 7 local recurrent 
tumors and 3 recurrent tumors of the neck. 
Th is subset of patients included 11 men 
and 10 women (median age 56 years, range 
37-83). Of these tumors, 7 (33%) were initially 
clinically classifi ed as T1, and 14 (67%) as 
T2. Histopathological evaluation classifi ed 11 
(52%) primary tumors as pT1, and 10 (48%) 
as pT2. Regarding primary surgical treatment, 
8 patients underwent no further treatment to 
the neck and 13 patients underwent elective 
3 PATIENTS AND METHODS
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neck dissection; 16 patients had occult neck 
metastases (i.e., lymph node metastases in the 
END specimen (n = 11) or the appearance 
of neck metastasis during follow-up without 
failure at the primary site (n = 5)). During 
follow-up, 8 of these patients developed local 
recurrence, 14 died of tongue cancer, and 4 of 
other causes.
Table 3. Patient-related and clinopathological 
features of the 73 patients with early-stage 
(clinically T1, N0 and T2, N0) oral tongue 
squamous cell carcinoma.
Clinocopathological variable No of patients (%)
Sex
  Male 36 (49)
  Female 37 (51)
Age, years
  ≤ 60 40 (55)
  > 60 33 (45)
  Range 23-95
  Median 59
Invasion depth (mm) 
  ≤ 4 29 (40)
  > 4 44 (60)
Grade
  I 24 (33)
  II 35 (48)
  III 14 (19)
Clinical T Stage 
  cT1 (≤ 20 mm) 35 (48)
  cT2 (21-40 mm) 38 (52)
Pathological T Stage
  pT1 (≤ 20 mm) 52 (71)
  pT2 (21-40 mm) 21 (29)
Pathological node positivity*
  pN0 26 (36)
  pN+ 15 (21)
Pathological Stage
  I 46 (63)
  II 12 (16)
  III 12 (16)
  IV 3 (4)
* 41/73 (56%) of the patients underwent elective neck 
dissection
3.2 Tissue microarray (I, II, III)
Tissue microarray (TMA) blocks were 
prepared from primary tumors. For TMA 
blocks, three diff erent invasion depth areas 
(surface, center, invasive front) from H&E 
stained slides were selected. From marked 
areas, six representative 1-mm cores from each 
tumor were detached and placed in a paraffi  n 
block with a manual tissue microarrayer 
(Beecher Instruments, Silver Spring, MD, 
USA) as described elsewhere (208,209). From 
all samples, two similar blocks were produced. 
In the fi nal analysis of each immunostaining 
representative, tissue was lacking for two 
to ten patients (for details, see the original 
articles). 
3.3 Immunohistochemistry (I, 
II, III, IV)
Paraffi  n blocks were cut into 4- to 5-μm 
sections. Th ese sections were then 
deparaffi  nized in xylene and rehydrated 
through a series of graded alcohol. Th e slides 
were treated in a PreTreatment module 
(LabVision Corp., UK Ltd., UK) with Tris-HCl 
buff er (pH 8.5) (all MMPs and TLRs 2, 4, 5, 
and 7) or EDTA buff er (pH 9.0) (TLR-9) for 
20 min at 98°C, followed by endogenous 
peroxidase blocking for 5 min with 0.3% Dako 
REAL Peroxidase-Blocking Solution. Th e 
immunostaining procedure was performed by 
an Autostainer 480 (Lab Vision Corp.) with 
primary antibodies (Table 4) for one hour (I, 
II, III), except in Study IV, where staining took 
place manually, and primary antibodies were 
added for 16 to 21 hours. Th is was followed 
by a 30-min incubation with a Dako REAL 
EnVision/HRP detection system and Rabbit/
Mouse (ENV) reagent. Dako REAL DAB+ 
Chromogen fi nally served to visualize the 
slides for 10 min. Between each step, the slides 
were washed with PBS-0.04%-Tween20. Slides 
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were counterstained with Meyer’s hematoxylin 
and mounted in mounting medium 
(Aquamount, BDH, Poole, UK). Tissues 
known to be highly positive for the proteins 
under study served as positive controls, and 
for negative controls, the specimens were 
processed with no primary antibody. Th e 
staining protocol for Ki-67 appears in Häyry 
et al. (126). In addition, we carried out 
MMP-7 immunostaining of non-neoplastic 
tongue tissue from six patients (II), and TLR 
immunostainings from ten patients (III). 
3.4 Scoring of 
Immunohistochemical 
stainings (I, II, III, IV)
Two independent researchers in each study 
(J.H. and F.P-S. in Studies I, II; L.K.M. and J.H. 
in Studies III, IV), blinded to the clinical data 
(I, II, III), evaluated the staining positivity of 
diff erent markers by evaluating the percentage 
of positively stained tumor cells and, in cases 
of disagreement, reached consensus. In tumor 
cells, the immunopositivity of MMP-2, -8, 
and -9 was cytoplasmic, but that of MMP-13 
was nuclear. Grading in Study I was carried 
out as follows:  0 = no positivity, 1 = up to 
10% positive tumor cells (low), 2 = 11-50% 
(moderate), 3 = 51-90% (high), 4 = over 90%, 
strong, intense overall positivity (very high). 
Concerning MMP-7 and -25, the percentage of 
positive tumor cells was evaluated as follows: 
no positivity was graded as 0, positive cells up 
to 20% as 1 (low), 21-50% as 2 (moderate), 
51-80% as 3 (high) and over 80% as 4 (very 
high) (II). Th e cytoplasmic staining intensity of 
TLR-2, -5 and -9 was scored as 0 for negative, 
1 for mild, 2 for moderate, and 3 for strongly 
Table 4. Antibodies used and staining patterns in OTSCC.
Antigen Primary antibody Dilution Staining pattern
MMP-2 NCL 507, Novocastra, Newcastle, UK, monoclonal 1:75 Cytoplasmic
MMP-7 Clone 141-7B2, Millipore, Temecula, USA, monoclonal 1:2000 Cytoplasmic
MMP-8 Hanemaaijer et al. (210) (Commercially unavailable) 1:100 Cytoplasmic
MMP-9 44236, Calbiochem, Merck KGaA, Darmstadt, Germany, polyclonal 1:1000 Cytoplasmic
MMP-13 IM44, Calbiochem, Merck KGaA, Darmstadt, Germany, monoclonal 1:50 Nuclear
MMP-25 M4942, Sigma, St Louis, USA, polyclonal 1:300 Cytoplasmic 
TLR-2 H-175, Santa Cruz Biotechnology, Inc, CA, USA, polyclonal 1:50 Cytoplasmic and/or nuclear 
TLR-4 H-80, Santa Cruz Biotechnology, Inc, CA, USA, polyclonal 1:50 Cytoplasmic and/or nuclear 
TLR-5 IMG-664A, Imgenex, San Diego, CA, USA, monoclonal 1:200 Cytoplasmic
TLR-7 IMG-581A, Imgenex, San Diego, CA, USA, polyclonal 1:300 Nuclear membranous
TLR-9 H-100, Santa Cruz Biotechnology, Inc, CA, USA, polyclonal 1:100 Cytoplasmic
p16INK4a Clone E6H4, 9511, CINtech® Histology Kit, Roche, Germany, monoclonal
Ready-to-
use Cytoplasmic
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positive. Nuclear TLR-2 staining, cytoplasmic 
TLR-4 staining, and nuclear membranous 
TLR-7 staining was scored according to the 
percentage of positive tumor cells as follows: 
0 = no positive cells, 1 = positive cells up 
to 10% (low), 2 = 11-50% (moderate), 3 = 
51-80% (high), and 4 = over 80% (very high). 
p16INK4a was classifi ed as positive when over 
70% of the cells were stained. Immunoscore 
of the primary tumors was evaluated from 
the surface and invasive front of the tumor. In 
organotypic myoma invasion assay, TLR-2, -4, 
and -9 staining positivity was scored in same 
manner as for OTSCC tumor tissue samples 
(A.A.). 
On the tissue array slides, six specimens 
from each tumor were evaluated, and, for each 
case, the highest immunoscore was selected 
for analysis (I, II, III). 
3.5 Cell culture and 
preparation of total cell 
lysates (III, IV)
Human oral tongue cancer cell line (HSC-3, 
JCRB0623), received from the Institute 
of Dentistry, University of Helsinki, was 
propagated in an equivalent amount of DMEM 
medium with 4.5 g/l glucose and Ham’s F12 
Nutrient mixture supplemented with 10% 
fetal calf serum (FCS), 100 U/ml penicillin 
and 100 μg/ml streptomycin, as well as 1 mM 
sodium pyruvate, 250  ng/ml fungizone and 
0.4  ng/ml  hydrocortisone (Sigma-Aldrich, 
St. Louis, MO). Cells were lysed in Nonidet 
P-40 (NP-40) lysis buff er (1% NP-40, 20 mM 
HEPES, pH 7.5, 150 mM NaCl) supplemented 
with 50 mM NaF, 1 mM Na3VO4 and 1 
x Complete Proteinase Inhibitor Cocktail 
(Roche, Basel, Switzerland) at 4°C for 30 min. 
Detergent-insoluble material was removed 
by centrifugation (16 000 x g at 4°C for 15 
min). Protein concentrations were measured 
by using the Bradford assay (Bio-Rad 
Laboratories, Hercules, CA, USA).
3.6 Western immunoblot (III)
Fift y μg of total cell lysates were separated 
with 10% SDS-PAGE, transferred to PVDF-FL 
membranes (Millipore, Billerica, MA) 
and blocked with Odyssey blocking buff er 
(LI-COR, Lincoln, NE) diluted to 1:1 with PBS. 
Th e membranes were incubated with rabbit 
anti-TLR-2 (Santa Cruz Biotechnology, Inc.), 
rabbit anti-TLR-4 (Santa Cruz Biotechnology, 
Inc.) and mouse anti-actin (Sigma) IgGs, 
followed by Alexa Fluor 680 (Invitrogen) and 
IRDye 800 (LI-COR Biosciences) anti-mouse 
or anti-rabbit IgGs. Th e signal was detected 
using an Odyssey Infrared Imager (LI-COR) 
and subsequently quantifi ed using Odyssey 
soft ware.
3.7 Myoma organotypic 
invasion assay and GIT27 
(IV)
To study the eff ect of TLR-2 and -4 antagonist 
GIT27 (Tocris Bioscience, Bristol, UK) on 
the invasion of the OTSCC cell line (HSC-3), 
we used organotypic myoma invasion assay. 
Myoma disks were preprared from uterine 
leiomyoma. Disks were placed into transwell 
inserts and on top of each myoma 800 000 
cells were added. Aft er 24h, the myomas were 
transferred to 12-well plates on a nylon disk 
resting on steel grids. Normal cell culture 
media without GIT27, 10 μg/ml or 30 μg/ml 
GIT27, was used. Media were changed every 
3-4 days, the myomas fi xed in formalin aft er 14 
days, and embedded in paraffi  n. Th e method 
is explained in more detail by Nurmenniemi et 
al. (211). 
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3.8 Statistical methods
We used SPSS 22.0 soft ware (IBM Corporation, 
NY, USA) and Prism 6 (GraphPad Soft ware 
Inc, San Diego, CA, USA) for the statistical 
analyses. A two-sided P-value of less than 
0.05 was considered statistically signifi cant. 
Immunoexpression scores of MMPs and 
TLRs were compared with clinicopathological 
variables: size (diameter and pT classifi cation), 
depth of invasion, tumor grade, the presence 
of occult neck metastases, and patients’ age 
and sex. Immunoexpression scores were 
dichotomized when appropriate. Spearman’s 
correlation and Fisher’s exact test or the χ2 
test served to analyse correlations between 
categorical variables. Similarly, the scores of 
TLR stainings were compared with p16INK4a 
staining scores (III). MMP-7 served as an 
explanatory variable in a logistic regression 
model to analyse the association between 
MMP-7, invasion depth and occult neck 
metastases. A proportional odds model served 
to analyse the association between MMP-7 
and grade. Ki-67 expression was analyzed as 
described by Häyry (126). 
In Study IV, TLR immunoexpression 
scores of primary tumors were compared to 
the TLR expression scores of metastases and 
recurrent tumors. Th e non-parametric Mann-
Whitney U test served to analyze statistical 
diff erencies between TLR staining patterns. 
Parametric tests (unpaired  t-test) served to 
test statistical signifi cances of in vitro tests. 
Th e Kaplan-Meier estimates, the log-rank 
test and a multivariate Cox regression model 
served to evaluate the immunoexpression 
scores of MMPs and TLRs. DSS time was 
defi ned as the interval between the date of 
the fi rst treatment (surgery) and death from 
tongue cancer or the end of follow-up. DFS 
time was calculated from the date of the fi rst 
treatment to the fi rst recurrence of the disease.
A multivariate analysis (Cox regression) 
performed in Study III included the following 
variables: pT-stage, grade, presence of 
occult neck metastases, invasion, and TLR-5 
immunoscores. Variables were selected in 
a backward stepwise manner, and a p-value 
of 0.05 served as the limit for inclusion of a 
covariate. Also, covariates previously shown 
to have prognostic value in OTSCC were 
selected.
3.9 Ethical conciderations 
Th e National Supervisory Authority of 
Welfare and Health, and the Research Ethics 
Committee at the Helsinki University Central 
Hospital approved the study design (Dnro 
166/E9/07). Because this retrospective study 
did not aff ect the treatment of the patients, nor 
were the individual patients identifi able from 
the research, the study design required no 
informed consent. 
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4.1 Matrix metalloproteinases 
(I, II)
4.1.1 MMP expression in OTSCC
Th e majority of OTSCCs expressed all of 
the MMPs under study (staining patterns 
appear in Figure 1). Th e score distributions of 
diff erent MMPs in OTSCC appear in Table 5. 
Tumor tissue material was available from 
71 patients for MMP-25 staining and from 
70 patients for other MMPs under study. 
MMP-2 staining showed that the frequency 
of immunopositive cells varied from low 
to very high. Most of the tumors (76%, 
53/70) exhibited low or moderate MMP-2 
immunopositivity. MMP-7 positivity was low 
(35/70, 50%) or moderate (21/70, 30%) in the 
majority of tumors, and only seven tumors 
had a high frequency of positive cells (7/70, 
10%). None of the samples showed very high 
immunopositivity. MMP-8 expression was 
high or very high in 74% (52/70) of the tumors. 
None of the tumors showed very high MMP-9 
frequency. Most tumors (76%, 53/70) showed 
low or moderate MMP-9 immunopositivity. 
MMP-13 expression was high or very high 
in the majority (77%, 54/70) of tumors and 
MMP-25 immunopositivity ranged from low 
to very high. 
None of the normal tongue tissue samples 
showed MMP-7 immunopositivity.
Table 5. Score distribution of six diff erent MMPs in OTSCC (n (%)).
  None = 0 Low = 1 Moderate = 2 High = 3 Very high = 4 Total positivity (%)
MMP-2 11 (16) 39 (56) 14 (20) 4 (6) 2 (3) 59/70 (84)
MMP-7 7 (10) 35 (50) 21 (30) 7 (10) 0 63/70 (90)
MMP-8 2 (3) 5 (7) 11 (16) 30 (43) 22 (31) 68/70 (97)
MMP-9 12 (17) 22 (31) 31 (44) 5 (7) 0 (0) 58/70 (83)
MMP-13 4 (6) 2 (3) 10 (14) 30 (43) 24 (34) 66/70 (94)
MMP-25 7 (10) 8 (11) 17 (24) 30 (42) 9 (13) 64/71 (90)
4 RESULTS
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Figure 1. Immunohistochemical staining of MMP-2 (A), -7 (B) -8 (C), -9 (D), -13 (E), and -25 (F) 
in oral tongue squamous cell carcinoma (x 60). MMP-13 expression is nuclear, and the expression of 
other MMPs under study occurs in the cell cytoplasm. Image: Jaana Hagström.
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4.1.2 Correlations between MMPs 
and clinicopathological 
variables
All correlations between MMPs and 
clinicopathological variables appear in Table 6. 
MMP-7 expression predicted a higher 
probability of occult cervical metastases (OR 
3.67, 95% CI 1.29-10.43, p = 0.013) as well 
as greater invasion depth. In tumors with an 
invasion depth over 4 mm, MMP-7 expression 
was usually high, whereas in tumors with a 
lower invasion depth, MMP-7 expression was 
correspondingly low (OR 4.60, 95% CI 1.47-
14.39, p = 0.005). 
High MMP-7 expression was associated 
with histologically poorly diff erentiated 
tumors (OR 3.30, 95% CI 1.27-8.57, p = 0.007, 
proportional odds model). We found no 
correlation between MMP-7 expression and 
tumor size (T stage), patient age or sex.
MMP-13 expression correlated with 
invasion depth (P = 0.017, Spearman’s 
correlation, P = 0.042, Fisher’s exact test) as 
well as with pT class (P = 0.008, Spearman’s 
correlation). MMP-13 expression showed 
no correlation with tumor grade or neck 
metastases, Ki-67-score, or patient’s sex or age. 
MMP-2, -8, -9 and -25 expression failed 
to correlate with any tumor or patient-related 
parameters.
4.1.3 Prognostic aspects of MMPs 
in OTSCC
MMP-7 expression predicted poor overall 
survival (OS) (p = 0.021) (Figure 2). Even 
though the Kaplan-Meier plot suggested a 
potential diff erence in disease-specifi c survival 
(DSS) between the groups, we found no 
statistical signifi cance. All patients with totally 
negative MMP-7 staining survived throughout 
the follow-up period. In contrast, 57% (4/7) of 
patients with high MMP-7 protein expression 
succumbed to OTSCC during follow-up. We 
also evaluated the eff ect of MMP-7 expression 
on disease-free survival time, but found no 
correlation. 
Results
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Figure 2. MMP-7 expression predicted poor overall survival (p = 0.021, log-rank test). Th e Kaplan-
Meier plot suggested a potential diff erence in disease-specifi c survival between the groups, but we 
found no statistical signifi cance.
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Figure 3. A Kaplan-Meier plot showing a signifi cant diff erence (p = 0.042, log-rank test) in the 
disease-specifi c survival of patients with no to high (scores 0–3) (dotted line) and very high (score 4) 
(solid line) MMP-13 expression. Th e diff erence between these two groups in overall survival was not 
signifi cant. 
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MMP-8 expression showed no correlation 
with any tumor or patient-related parameters, 
and no signifi cant diff erences in outcome 
emerged. However, the DFS time was shorter 
in groups with negative (n = 2) and very strong 
(n = 22) MMP-8 expression than in those 
with low to high (n = 46) immunoexpression, 
although this diff erence failed to reach 
signifi cance (data not shown).
Very high MMP-13 expression predicted 
poor DSS (very high intensity vs. others, p = 
0.042, log-rank test, Figure 3). Th e fi ve-year 
DSS of patients with no to high MMP-13 
expression was 82% (95% CI 71-93%), 
compared to 63% (95% CI 43-83%) for 
patients with very high MMP-13 expression, 
as the Kaplan-Meier plot also showed. Th e 
correlation with DFS time failed to reach 
statistical signifi cance. 
Th e expression of gelatinases MMP-2 and 
-9 or membrane-type MMP MMP-25 showed 
no correlation with any prognostic variables. 
4.2 Toll-like receptors (III, IV)
4.2.1 TLR expression in OTSCC 
(III, IV)
All the diff erent TLRs examined were 
expressed in OTSCC tissue (staining patterns 
appear in Figure 4). Figure 5 shows their 
score distribution in tissue array samples 
(III) in detail. Th e majority of the tumors 
showed moderate or strong/high or very 
high expression of nuclear and cytoplasmic 
TLR-2 and cytoplasmic TLR-4. TLR-5 
immunoexpression was moderate or strong in 
most of the tumors. Th e nuclear membranous 
positivity of TLR-7 was present mostly at a low 
or moderate level. TLR-9 expression occurred 
mainly at a mild or moderate level. Only six 
tumors showed strong TLR-9 expression. 
Most primary and recurrent tumors and 
neck metastases expressed TLR-2, -4, and 
-9. In tissue array specimens, nuclear TLR-4 
positivity occurred so seldomly that we did not 
Figure 4. Immunohistochemical staining of TLR-2 (A), -4 (B), -5 (C), -7 (D), and -9 (E) in oral tongue 
squamous cell carcinoma (x 40). TLR-2 expression is nuclear and cytoplasmic, TLR-4 expression is 
mainly cytoplasmic, TLR-7 expression is nuclear membranous, and TLR-5 and -9 expression occurs 
in the cell cytoplasm. Image: Jaana Hagström.
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A B 
D E 
C 
29
score it, whereas whole tissue samples from 
primary tumors presented with scarce nuclear 
TLR-4 positivity, and was scored separately 
from the surface of the tumor and the invasive 
front. Th e expression of TLR-4 and -9 on the 
surface of the primary tumor diff ered from 
that on the invasive front. Cytoplasmic TLR-4 
was stronger at the invasive front (p < 0.001, 
Mann-Whitney U-test), whereas nuclear 
TLR-4 expression was stronger on the surface 
of the tumor (p = 0.038, Mann-Whitney 
U-test). Th e invasive front showed stronger 
cytoplasmic TLR-9 expression on the surface 
of the tumor (p = 0.002, Mann-Whitney 
U-test). 
Primary tumors expressed nuclear 
TLR-2 more oft en than did neck metastases 
or recurrent tumors of the neck (p = 0.006, 
Mann-Whitney U-test), whereas nuclear 
TLR-4 expression (p = 0.036, Mann-Whitney 
U-test) and cytoplasmic TLR-9 expression (p 
= 0.08, Mann-Whitney U-test) were higher 
in primary tumors than in local recurrent 
tumors.
Figure 5. Score distributions of nuclear TLR-2, nuclear membranous TLR-7, and cytoplasmic TLR-2, 
-4, -5, and -9 expression in tissue microarray samples of oral tongue squamous cell carcinoma.  
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4.2.2 TLR Expression in non-
neoplastic tongue tissue (III)
TLRs also occurred in non-neoplastic tongue 
tissue, but expression diff ered somewhat from 
that in cancer tissue. We observed TLR-2 
positivity in the nucleus and cytoplasm in 
both non-neoplastic and carcinoma tissue, 
but expression was stronger in carcinomas. 
Nuclear expression of TLR-4 was stronger in 
non-neoplastic tissue samples than in OTSCC, 
which had such scarce TLR-4 positivity in the 
nucleus that we did not score it. Cytoplasmic 
TLR-4 positivity occurred more oft en in 
carcinoma than in benign tissue. Cytoplasmic 
TLR-5 immunoexpression was moderate or 
strong in most of the benign and malignant 
samples. TLR-7 was nuclear membranous in 
both non-neoplastic and malignant tissue. 
TLR-9 expression was cytoplasmic in both 
benign and carcinoma tissue.
4.2.3 TLR-2 and -4 in Western 
Blot analysis (III)
Western blot analysis confi rmed that TLR-2 
and -4 expression occurred in the HSC-3 
tongue carcinoma cell line, and that their 
molecular weights corresponded with those of 
full-length proteins.
4.2.4 Correlations between TLRs 
and clinicopathological 
variables (III)
All correlations between TLRs and 
clinicopathological variables appear in Table 6. 
Both high cytoplasmic TLR-2 and TLR-4 
expression correlated with deeper tumor 
invasion (p = 0.026 and p = 0.008, respectively, 
Spearman’s rho) and higher tumor grade 
(p = 0.021 and p = 0.005, Spearman’s rho), 
whereas high TLR-5 expression correlated 
with lower tumor grade (p = 0.039, Spearman’s 
rho). High TLR-9 expression correlated with 
deeper tumor invasion (p = 0.019, Spearman’s 
rho) and larger tumor diameter (p = 0.003, 
Spearman’s rho). Nuclear expression of TLR-2 
or membranous expression of TLR-7 failed to 
correlate with any of the variables.
4.2.5 Prognostic aspects of TLRs 
in OTSCC (III)
None of the TLRs correlated with disease 
recurrence. In survival analyses, negative 
or mild (group 0, n = 4) TLR-5 expression 
predicted poor DSS (p = 0.014, log-rank 
test) and poor OS (p = 0.005, log-rank test) 
(Figure 6), yet multivariate analysis failed to 
show TLR-5 expression as an independent 
prognostic factor in OTSCC. Survival analyses 
revealed no other signifi cant correlations. 
4.2.6 Myoma organotypic 
invasion assay and GIT27 
(IV)
In organotypic myoma invasion model assay, 
GIT27 failed to inhibit the invasion of HSC-3 
cells into the myoma tissue. Th e mean invasion 
depths were 2.2 mm without GIT27, 3.0 mm 
with 10 μg/ml GIT27, and 2.5 mm with 30 
μg/ml GIT27. However, the expression levels 
of TLR-2 and -4 varied between the surface 
and invasive front. TLR-2 and -4 expression 
was stronger in cells invading deeper into the 
myoma than in cells close to the surface, which 
showed only minimal levels of these proteins. 
TLR-9 expression was consistent throughout 
the OTSCC cells in the myoma tissue.
4.3 p16 expression (III)
p16INK4a was positive in 9% (n = 6/65) of the 
OTSCC samples, and its expression failed to 
correlate with any of the clinicopathological 
factors or with TLR expressions.
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Figure 6. A Kaplan-Meier plot showing a signifi cant diff erence in the disease-specifi c survival (p = 
0.014, log-rank test) and overall survival (p = 0.005, log-rank test) of patients with negative or mild 
(scores 0–1) (dotted line) and moderate or high (score 2-3) (solid line) TLR-5 expression. 
Results
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5.1 Strengths and limitations 
of this thesis
In this thesis, we examined the expression 
and clinical signifi cance of MMPs and TLRs 
in a uniform sample of 73 patients with 
clinically early-stage OTSCC. Th ese proteins 
were previously evaluated in the HNSCCs of 
diff erent subsites, but many of those studies 
included patients in diff erent stages of the 
disease. However, early- or advanced-stage 
OTSCC involves malignancies with diff erent 
manifestations and outcomes. We included 
only T1-2 tongue tumors, as they can in 
practice always undergo surgery with adequate 
margins, yet many of them develop occult 
metastases, recur or behave aggressively. 
Th us, such a patient population off ers a sound 
basis for examining diff erences in protein 
expressions and for comparing expressions 
with tumor behavior. It is worth noting that 
the pathological classifi cation of some of our 
patients also indicated advanced-stage tumors, 
as some patients had occult metastasis in 
END or, if no END was performed, during the 
follow-up period. 
Patients underwent diagnosis and 
treatment between 1992 and 2002, which 
provided a long follow-up period of at least 
fi ve years. Treatment of OTSCC has changed 
little in recent decades, and patients in this 
sample received treatment according to the 
Finnish national treatment guidelines for head 
and neck cancer. For example, all patients 
with occult neck metastases also received 
post-operative radiotherapy. However, various 
treatment modalities may obviously constitute 
a confounding factor for retrospective 
outcome analyses. Nevertheless, even in a 
prospective study and population setting, a 
number of confounding factors, such as the 
smoking habits of the patients, vary, as does 
the treatment of the neck. Moreover, had we 
selected an even more uniform patient group, 
the study would have had too few patients.  
Studies I-III were performed using the 
TMA technique, which is a method for easily 
studying a large number of molecular markers. 
Furthermore, although the TMA technique 
requires little valuable tissue material, it has 
its limitations (212). Because a single TMA 
sample requires only a small (1 mm) punch 
from each area of the tumor, possible variations 
in protein expression in diff erent parts of the 
tumor can skew evaluations of expression. 
Th is study used three core tissue biopsies 
from each tumor: from the tumor surface, the 
middle part, and the invasive front, yielding 
two similar TMA blocks; thus, we evaluated 
six histospots of each tumor. However, Studies 
I-III, which used the TMA technique, failed 
to evaluate the immunoexpression scores 
according to the localization of each biopsy. 
Evaluating diff erences in expression between 
the surface and the invasive front of the 
tumor was therefore impossible. Comparing 
expressions across diff erent sites of the tumor 
was possible in Study IV, which used whole 
tissue slides.  
Th e absence of data on patients’ smoking 
and alcohol consumption could be considered 
a shortcoming of this study, because smoking 
and alcohol are the well-known risk factors in 
OTSCC and variables possibly aff ecting the 
survival and comorbidity of these patients. 
A prospective study, however, could take this 
absence of data into consideration.
Study IV assessed the eff ect of TLR-2 
and -4 antagonist GIT27 on the invasion of 
the OTSCC cell line. Our study used only one 
highly invasive OTSCC cell line, so our results 
may not be representative of most OTSCC 
5 DISCUSSION
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cells. To draw more defi nite conclusions, the 
study should also examine some other cell 
lines. 
5.2 MMPs in OTSCC (I, II)
MMP-7 upregulation correlated with 
tumor invasion, neck metastasis and 
grade, and predicted poor survival 
In the present study, MMP-7 expression 
associated with invasion, metastasis, and poor 
OS. Th e fi ndings of some previous studies of 
colorectal, pancreatic, and bladder cancer 
agree with this fi nding of a correlation between 
MMP-7 upregulation and metastatic disease 
(146,148,149,213). Furthermore, another 
study which included oral cancers of diff erent 
sites and stages found that MMP-7 expression 
correlated with lymph node metastasis (58). 
Other MMPs (MMP-1, -2, -3, -7, -9, -13, 
-14) have also been linked to the presence of 
metastases in various cancers (48).
In buccal squamous cell carcinoma, 
overexpression of MMP-7 correlated with 
larger tumor size and more aggressive invasion 
of adjacent tissues (157). Likewise, our 
results showed that high MMP-7 expression 
associated with advanced invasion depth, 
whereas  in our material, MMP-7 expression 
showed no correlation with T classifi cation. 
Th is discrepancy may be due to previously 
reported diff erences in the behavior of OTSCC 
from that of OSCCs from other subsites 
(26,27). Furthermore, de Vicente et al. found 
a correlation between MMP-7 expression and 
invasion in OSCC from diff erent subsites (58). 
However, in contrast to our results, they found 
no association with histological tumor grade. 
In this study, MMP-7 expression 
predicted poor OS. However, we found no 
statistical signifi cance between MMP-7 
expression and DSS, although such a tendency 
was evident. Th is could be due to the small 
number of patients in groups with no (0%, n = 
7) or high (51-80%, n = 7) MMP-7 expression. 
In addition, patients with tumors lacking 
MMP-7 expression survived throughout 
the follow-up period, whereas patients with 
high MMP-7 expression had poor DSS. Our 
fi ndings call for further study to confi rm 
the possible prognostic value of MMP-7 
expression for survival.
As our present results suggest, MMP-7 
expression may also have prognostic 
signifi cance in other cancers, including 
bladder, liver, gastric, pancreatic and 
colorectal cancers (146,147,149,150,213-
215). Another study of 29 patients with 
OTSCC found an association with MMP-7 
overexpression and shortened survival, but 
the correlation was signifi cant only among 
patients with positive lymph nodes (58). 
Weber et al. studied MMP-7 expression in 
tumors of the oropharynx, hypopharynx and 
larynx, and found that MMP-7 associates with 
survival in univariate, but not in multivariate 
analyses (59). Lequerica-Fernandez also 
studied MMP-7 in carcinoma of the parotid 
gland, but found no prognostic signifi cance 
(216). In contrast to our results, Luukkaa et 
al. found an association between low MMP-7 
expression and poor survival in acinic and 
mucoepidermoid carcinomas of the parotid 
gland (177). 
Th is is the fi rst study of a uniform 
patient material with early-stage OTSCC to 
demonstrate that MMP-7 overexpression 
associates with more aggressive disease. 
MMP-13 overexpression correlated 
with deeper invasion and advanced 
tumor size and associated with poor 
survival
We found that MMP-13 expression to predict 
more aggressive tumor invasion and growth as 
well as poor DSS in OTSCC. Previous studies 
have shown that MMP-13 plays a role in 
tumor progression and HNSCC invasion (56), 
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as well as in other cancers (172,173). Marcos 
et al. demonstrated that upregulation of serum 
MMP-13 levels correlated with active MMP-13 
and lymph node metastasis in HNSCC (175), 
which was in accordance with our results 
indicating that high MMP-13 expression 
associates with more aggressive disease.
Th e fi nding of an association between 
very high MMP-13 immunoexpression and 
poor DSS is in accordance with that of a study 
by Luukkaa et al., who examined stage I-IV 
HNSCCs from diff erent subsites (57). Th ey 
also suggested that high MMP-13 staining 
intensity predicts poor overall survival in 
salivary gland cancer (176). 
With regard to disease recurrence, 
Luukkaa et al. previously reported a slight, 
but non-signifi cant, association between 
MMP-13 expression and DFS in HNSCC (57). 
In our study, however, we found no signifi cant 
correlation between MMPs and DFS either.
Th is study demonstrates a correlation of 
nuclear MMP-13 expression with invasion 
depth, tumor size, and DSS in early-stage 
OTSCC. Our results, regarding the tissue 
expression of MMP-13 in OTSCC strengthen 
and extend the previous fi ndings of Marcos 
et al., who proposed that elevated serum 
MMP-13 levels are a potential tumor 
biomarker in HNSCC (175). Overall, MMP-13 
may be a prognostic biomarker of tongue 
cancer, but verifying its role in clinical use will 
require further studies of tumours from other 
head and neck sites. 
MMP-2, -8, -9, and -25 in OTSCC
In the present study, the expression of 
gelatinases MMP-2 and -9 correlated with 
none of the clinicopathological or prognostic 
variables.
A study by Kurahara et al. found that 
MMP-2 and -9 expression to correlates with 
regional metastasis OSCC (54). In contrast, a 
meta-analysis of MMPs in HNSCC reported 
no correlation between MMP-2 and -9 
expression and nodal metastasis, which 
is in accordance with our results (217). 
O-Charoenrat et al. found a correlation 
between MMP-9 overexpression and 
advanced T-stage, an infi ltrative pattern of 
tumor growth, and lymph node involvement, 
whereas MMP-2 expression and lymph node 
status showed only a weak correlation (165). 
Likewise, Hong et al. found that MMP-9 
expression related signifi cantly to metastasis 
in OSCC, whereas MMP-2 expression did 
not (160). Th ey suggested that MMP-9 may 
play a more important role than MMP-2 in 
the metastasis of OSCC to adjacent tissues. 
Our study, however, failed to verify this 
possible infl uence of MMP-2 and MMP-9 on 
metastasis in OTSCC. 
Studies by Ruokolainen et al. found that 
both MMP-2 and -9 associated with shorter 
DSS and DFS in HNSCC (169,170). Similarly, 
MMP-2 expression proved to correlate with 
tumor recurrence as well with poor DFS (55). 
Katayama et al. observed that MMP-9 had 
predictive value in metastasis and DSS in 
early-stage (T1N0M0 and T2N0M0) OSCC 
(162). However, similar to our fi ndings, 
Korpi et al. found no correlation between the 
immunohistological staining of MMP-2 or -9 
and the DSS of OTSCC patients (51). 
Most of our patients presented with 
tumors showing high or very high MMP-8 
expression. MMP-8 has reportedly acted as a 
protector against the spread of skin (52), breast 
(140), and tongue (51) cancers. However, we 
found no defensive eff ect of MMP-8 in OTSCC. 
It is worth noting that only two patients in our 
sample showed negative MMP-8 expression. 
Th us, we could draw no conclusion about 
the protective role of MMP-8. In survival 
analyses, patients with negative (n = 2) and 
very strong (n = 22) MMP-8 expression had 
a shorter DFS time than did patients with low 
to high (n = 46) immunoexpression, but this 
diff erence did not reach statistical signifi cance. 
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We hypothesized that MMP-8 expression and 
its action on bioactive chemokines, cytokines, 
and growth factors at ‘normal’ levels may 
play a protective role in cancer (50,51,218). 
However, when MMP-8 is totally missing or 
clearly overexpressed, this protection may be 
lost. Very highly expressed proteins may have 
mutated and therefore altered their normal 
function. 
To our knowledge, no previous studies 
have examined MMP-25 in HNSCC. Although 
some studies have reported MMP-25 
expression in some malignancies (154,156), 
the role of MMP-25 in cancer remains 
inconclusive. In our patients, MMP-25 was 
expressed in most OTSCC tumors, but we 
found no correlation with clinicopahtological 
parameters. Its role in OTSCC therefore 
requires further investigation.
 
Conclusion
Our results on MMPs in a uniform sample 
of early-stage OTSCC suggest that MMP-7 
overexpression could contribute to OTSCC 
tumor invasion and metastasis, and that 
upregulation of MMP-13 may predict even 
more aggressive tumor invasion and growth. 
Both MMP-7 and -13 expressions associated 
with poor patient survival. 
5.3 TLRs in OTSCC (III, IV)
TLR expression in non-neoplastic 
tongue tissue
TLRs were widely expressed in OTSCC tissue, 
as previous studies on TLRs in HNSCC have 
also reported (70-77). We also evaluated 
TLR expression in non-neoplastic tongue 
tissue, in which TLRs were expressed but 
staining patterns diff ered somewhat from 
those in carcinoma tissue. Cytoplasmic TLR-2 
expression was lower in benign tissue than 
in tumors, but both benign and malignant 
samples showed substantial nuclear TLR-2 
positivity. 
Ng et al. demonstrated clearly higher 
nuclear and cytoplasmic TLR-2 expression 
in the infl ammatory and endothelial 
cells in the OSCC microenvironment, 
and in dysplasia, than in the hyperplastic 
epithelium, which suggests that altered 
cells trigger immune surveillance (183). In 
our series, TLR-4 expression was widely 
present in both cancer and non-neoplastic 
tissues, but expression was mainly nuclear 
in benign and cytoplasmic cancer tissue. 
In a previous study by Szczepanski et al., 
cytoplasmic TLR-4 expression was weaker 
in the normal epithelium than in LSCC and 
OSCC tissues (75). Furthermore, Sun et al. 
also found TLR-4 expression, although low, in 
normal mucosa next to OSCC (182). Strong 
cytoplasmic TLR-5 expression occurred in 
both non-neoplastic and malignant tissues 
in the present series, whereas Kauppila et al. 
found stronger cytoplasmic TLR-5 expression 
in OTSCC than in the normal epithelium (70). 
Both benign and malignant tissues in our 
study showed nuclear or nuclear membranous 
TLR-7 staining or both. To our knowledge, 
no previous studies have examined TLR-7 
expression in OSCC tissue samples or normal 
oral mucosa. In our study, cytoplasmic TLR-9 
was mildly or moderately expressed in both 
benign and malignant tissues, whereas Min et 
al. reported higher TLR-9 expression in OSCC 
than in adjacent normal mucosa (73).
TLR expression and 
clinocopathological variables
In our samples, TLR-2, -4, and -9 
overexpression correlated with deeper 
tumor invasion. A study of TLR-2 in gastric 
cancer showed that high TLR-2 expression 
promoted the transcription of genes related to 
angiogenesis and invasion, and that expression 
correlated with metastasis (64). Th e same 
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study found that TLR-2 stimulation enhanced 
the invasive capacity of gastric cancer cells. In 
contrast, another study by Park et al. found 
no evidence of TLR-2 or -5 activation or its 
infl uence on the invasion of OSCC cells (196). 
Szczepanski et al. showed that TLR-4 ligand 
LPS enhanced HNSCC cell proliferation and 
that TLR-4 activation protected tumor cells 
from NK-92 cell-mediated lysis (75). Th ey 
concluded that TLR-4 ligation facilitates 
HNSCC progression. Th us, our result showing 
a correlation between TLR-4 expression and 
tumor invasion is in accordance with the 
results of this previous study. A recent in vitro 
study by Ruan et al. demonstrated that TLR-9 
activation induced the migration and invasion 
of OSCC cells (194), which supports our 
results.
In our material, TLR-2 and -4 
overexpression correlated with poor tumor 
diff erentiation. In contrast, strong TLR-5 
expression occurred in well-diff erentiated 
tumors. Studies have shown that TLR 
expression correlates with tumor grade in 
HNSCC: one study showed that high TLR-4 
expression correlated with a low grade in 
LSCC (75) and OSCC (182), whereas another 
study showed that high TLR-3 expression 
correlated with poorly diff erentiated OSCCs 
(71). However, grade is not considered a very 
reliable prognostic predictor in OSCC, mainly 
because of its subjective assessment (34). 
As a previous study of TLR-9 in OSCC 
also reported (73), in our material, high 
TLR-9 expression correlated with advanced 
tumor size. In OSCC, TLR-9 stimulation with 
CpG-ODN also increased tumor proliferation 
in vitro (73). 
TLR expression and survival in OTSCC 
Survival analyses revealed that patients 
with tumors showing no or mild TLR-5 
expression had worse DSS than did patients 
with moderate or high TLR-5 expression. Th is 
fi nding diff ers from that of Kauppila et al., 
who found strong TLR-5 expression to be an 
independent predictor of OTSCC mortality 
(70). However, one explanation could be that 
their study comprised OTSCC patients in 
diff erent stages of the disease, whereas our 
study focused only on early-stage disease. 
TLR-2 and -4 in Western immunoblot
We used Western immunoblot to study TLR-2 
and -4 expression in the OTSCC cell line. 
TLR-2 and -4 were expressed in OTSCC cells 
at their expected molecular weights of 90 kDa 
and 91 kDa, respectively. Th is in an interesting 
fi nding, because studies generally report that 
TLR expression occurs on the cell surface 
(60). Th us, our results show that expression 
of these TLRs occurred in their full-length 
forms in this tongue cancer cell-line even 
though in cancer tissue they were located in 
the cytoplasm. 
p16 expression in OTSCC
In these patients, we observed p16 positivity 
in only 9% of the tumors, which is similar to 
fi ndings from previous studies of p16 in OSCC 
(202-204). We found no correlation between 
p16 expression and clinicopathological 
parameters or with TLR expression. 
TLR expression in metastatic and 
recurrent OTSCC (Study IV)
For Study IV, we used whole-tissue samples 
to further study the role of TLRs in tumor 
invasion, metastases, and recurrences. In 
addition, we wanted to evaluate whether TLR 
expression on the surface of the tumor would 
diff er from that on the invasive front. 
Most primary tumors expressed TLR-2, 
-4, and -9 excessively. TLR expression in 
primary tumors diff ered somewhat from that 
in recurrent tumors or metastases. Nuclear 
TLR-2 expression occurred more oft en in 
primary tumors than in neck metastases or 
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recurrent tumors of the neck. Primary tumors 
showed higher nuclear TLR-4 expression and 
cytoplasmic TLR-9 expression than did local 
recurrent tumors. Th ese fi ndings suggest that 
TLRs contribute to OTSCC development and 
progression, but that the role of TLRs may 
diff er in the diff erent stages of the disease. 
Sharma et al. have recently reviewed 
the molecular changes at the invasive front 
of oral cancer (219). Th e authors pointed 
out that many of the molecular events that 
are essential for tumor spread take place at 
the tumor-host interface or invasive front, 
where the deepest and presumably most 
aggressive cells exist. Th ese events include, 
for example, changes in adhesion molecules, 
the production of proteolytic enzymes, 
increased cell proliferation and the triggering 
of angiogenesis. We also evaluated TLR 
expression separately at the surface of the 
primary tumor and at the invasive front. 
Cytoplasmic TLR-4 and TLR-9 expression 
was stronger at the invasive front than in the 
superfi cial tumor part of the tumor. In turn, 
stronger nuclear TLR-4 expression occurred 
on the tumor surface. Changes in TLR-4 
expression from nuclear at the surface to 
cytoplasmic in the deeper parts of the tumor 
could possibly refl ect the functional change 
of TLRs in tumor progression. As reported 
previously, TLR-2 and -4 normally occur on 
the cell surface, whereas TLR-9 expression 
usually occurs intracellularly (60). However, 
TLR expression may vary across diff erent 
tissues from nuclear to cytoplasmic or 
membranous or a combination of these. In a 
recent review, Jouhi et al. speculated the role 
of diff erent TLR expression patterns in cancer 
progression (220). Th ey hypothesized that 
the relocation of DAMPs in the cytoplasm 
of cancer cells could also activate TLRs in 
the cytoplasm, ultimately leading to tumor 
progression. However, the mechanisms 
behind diff erent localizations of TLRs in cells 
remains elusive. 
Myoma organotypic invasion assay 
We used myoma organotypic invasion assay 
to examine the invasion of the OTSCC HSC-3 
cell line. TLR-2 and -4 expression was stronger 
in cells invading deeper into the myoma tissue, 
whereas TLR-9 expression was consistent 
throughout the tumor cells. Th us, TLRs may 
infl uence the invasion of OTSCC.
Generally, TLRs are associated with the 
aggressive and invasive potential of cancer. A 
study by Yang et al. found TLR-2 stimulation 
to enhance the invasive capacity of gastric 
cancer cells in vitro (64). In HNSCC, TLR-4 
ligation on tumor cells has been linked to 
HNSCC progression (75). Furthermore, 
another study found TLR-9 activation to 
induce the migration and invasion of OSCC 
cells (194).
TLR-2 and -4 antagonist GIT27 did 
not aff ect the invasion of HSC-3 cells in 
organotypic myoma invasion assay. TLRs 
could utilize a diff erent action mechanism, 
whether activated by DAMPs in cancer or by 
PAMPs in infection. Maksimovic-Ivanic et 
al., who studied the  anti-cancer properties 
of GIT27  in rodent and human tumor cell 
lines (221), found that NO-donating isoxazole 
derivative GIT-27NO had anti-tumor 
properties and aff ected the viability of tumor 
cells, whereas the NO-deprived parental 
compound GIT27 had no impact on tumor 
cells. However, we could fi nd no similar anti-
tumor eff ect. One explanation for the diff erent 
fi nding may be that the HSC-3 cell line is 
highly aggressive with invasive potential. 
Furthermore, we studied the eff ect of GIT27 
on the invasion of tumor cells, not the viability 
HSC-3 cells. A previous study reported that 
although TLR-5 ligand fl agellin did not aff ect 
the invasion of HSC-3 cells, it did induce the 
proliferation, migration and invasion of less-
aggressive mucocutaneous cell lines (67). 
To our knowledge, no previous studies have 
examined GIT27 in HNSCC, although reports 
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have shown that TLR-4 ligand LPS induced 
proliferation and cytokine production in the 
OSCC cell line PCI-30, but not in another 
OSCC cell line, YD-10B (75,196).  
Conclusion
To summarize, TLR-2, -4, -5, -7, and -9 
expression occurred in OTSCC. TLR-2, -4, and 
-9 associated with invasive tumor growth, and 
expression of these TLRs occurred in primary 
tumors, neck metastases, and recurrent 
tumors. Consequently, these proteins may 
contribute to both the development and 
progression of tongue carcinoma. Changes in 
TLR expression from the surface of the tumor 
to the invasive front could refl ect a functional 
change of TLR action in cancer progression. 
5.4 Future perspectives
Our study comprised 73 OTSCC patients. 
Future studies should test our fi ndings in 
another, preferably larger, series of tumors 
to further clarify the role of these proteins 
in OTSCC. Of particular interest should be 
those proteins that showed an association 
with tumor behavior and outcome, namely 
MMP-7 and -13, as well as TLR-2, -4, and 
-9. Identifying biomarkers that could aid in 
evaluating the aggressiveness and prognosis 
of the disease would be most useful. Such 
markers might permit more appropriate and 
individualized treatment for each patient. 
Clarifi cation of the true meaning of these 
markers for disease survival would require a 
prospective randomized controlled trial. 
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6 CONCLUSIONS
1. MMP and TLR expression occurred in OTSCC.
2. MMP-7 overexpression associated with deeper tumor invasion, the presence of occult 
neck metastases, and poor OS.
3. High MMP-13 expression correlated with advanced tumor size and deeper tumor 
invasion, and associated with poor DSS.
4. TLR-2, -4, and -9 expression correlated with deeper tumor invasion. 
5. TLR-2 and -4 antagonist GIT27 failed to inhibit the invasion of the HSC-3 OTSCC cell 
line in the myoma-organotypic invasion model.
6. Th e expression patterns of TLR-2 and -4 at the surface of the primary tumor diff ered 
from those at the invasive front, which may refl ect functional changes in these TLRs 
during cancer progression. 
7. TLR-2, -4, and -9 expression occurred in primary tumors, neck metastases, and 
recurrent tumors. Th us, TLRs may contribute to OTSCC in diff erent stages of the 
disease. 
Both MMPs and TLRs appear to aff ect immune defence. Environmental carcinogens (e.g., 
tobacco, alcohol) are well known to contribute signifi cantly to the development of HNSCCs, 
whereas tumor progression could result partly from a failure of the innate immune response 
against cancer. Th us, the relevance of this innate immune response in cancer initiation and 
progression is the subject of intense research. Along with surgery, radiation, and chemotherapy, 
immunotherapy is likely to become the fourth means of treating cancer. How ctDNA released 
from tumor cells and NGS used to detect genomic alterations in tumors can serve in cancer 
diagnostics and treatment remains to be seen. 
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